How to Reduce Thyroid-Related Side Effects

Abstract

The present disclosure is directed to methods of administering thyroid hormone receptor agonists. [Solution] The present disclosure provides methods for improving or curing obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and related disorders, while maintaining the activity of a given thyroid receptor agonist, while reducing or eliminating thyroid-related and thyroid axis-related side effects.

Description

[Technical field]

[0001] The compounds and methods described herein relate generally to the field of treatment of thyroid-mediated disorders, and in particular to mechanisms that reduce the side effects resulting from administration of thyroid hormone receptor agonists. [Background technology]

[0002] Thyroid hormones (THs) play vital roles in growth, development, metabolism, and homeostasis. They are produced by the thyroid gland as thyroxine (T4) and 3,5,3'-triiodo-L-thyronine (T3). T4 is the major secreted form in humans and is enzymatically deiodinated by deiodinase to the more active form T3 in peripheral tissues. THs exert their actions by interacting with thyroid hormone receptors (TRs), which belong to the nuclear hormone receptor superfamily, and regulate the transcription of target genes. THs form part of the thyroid axis, also known as the hypothalamic-pituitary-thyroid, or HPT, axis, which involves complex endocrine and paracrine feedback loops that link brain tissue with the endocrine system to exert global control over a host of issues, including overall metabolic rate, lipid secretion, cardiac function, and muscle and bone growth (see, e.g., Robins and Cotran: Pathologic Basis of Disease, Kumar, V. et al., eds. (2005), p. 1165, the contents of which are incorporated herein by reference).

[0003] TR is expressed in many tissues and exists as two isoforms (TRα and TRβ). Tissue distribution studies, mouse knockout studies, and evaluation of patients with thyroid hormone resistance (RTH) syndrome have established that TRα is the predominant isoform in the heart and regulates most cardiac functions, while the TRβ isoform predominates in the liver and pituitary gland, regulating cholesterol metabolism and thyroid-stimulating hormone (TSH) production, respectively. Recognizing the possible benefits associated with TR modulation, many approaches have been pursued to identify TR agonists suitable for lowering plasma cholesterol levels. However, these benefits have been counterbalanced by adverse cardiovascular side effects such as tachycardia, arrhythmias, elevated blood pressure, and heart failure, as well as effects on the thyroid hormone axis, muscle metabolism, and bone loss.

[0004] TR-mediated pathways are involved in regulating serum lipid levels, including cholesterol, triglycerides, and related lipoproteins. See Pearce, EN, Curr. Cardiol. Rep. 6:451-6 (2004) and Duntas, LH, Thyroid 12:287-93 (2002), both of which are incorporated herein by reference in their entirety. Elevated serum lipid levels are involved in the development of atherosclerosis and the aggravation of coronary artery disease. See Robins and Cotran: Pathologic Basis of Disease, Kumar, V. et al., eds. (2005), 523, 572-77, the entire contents of which are incorporated herein by reference. Clinical trials have demonstrated that lowering low-density lipoprotein / serum cholesterol levels reduces morbidity and mortality associated with cardiovascular disease. See Grundy, SM et al., Circulation 110:227-39 (2004), the entire contents of which are incorporated herein by reference. Drugs such as statins and PCSK-9 inhibitors, along with dietary and lifestyle interventions, can help treat hyperlipidemia in some patients, but many patients are unable to significantly lower their serum cholesterol levels, and many cannot tolerate high doses of statins. See Pearson, T. et al., Arch Intern Med. 160:459-467 (2000), the entire contents of which are incorporated herein by reference. Thus, there is an unmet medical need for additional orally administered lipid-modulating therapies.

[0005] Similarly, nonalcoholic fatty liver disease (NAFLD), a condition associated with a group of metabolic abnormalities known as metabolic syndrome, is defined by excess fat accumulation in the form of triglycerides (steatosis) in the liver. The condition may further include hepatocellular injury and inflammation leading to nonalcoholic steatohepatitis (NASH). NASH is commonly found in patients with type 2 diabetes, hypercholesterolemia, hypertriglyceridemia, and obesity. Patients with NASH are at risk of developing cirrhosis, liver failure, and hepatocellular carcinoma. Treatment of NASH is currently limited to lifestyle interventions. However, the role of thyroid hormone in regulating LDL-C and triglyceride levels makes the TR-mediated pathway a promising target for the treatment of NASH and NAFLD. For example, in animals, thyroid hormone mimetics have been shown to dramatically reduce liver fat content.

[0006] Selective TRβ agonists have been developed as a means to suppress the cardiac side effects of non-specific TR agonists while retaining the possible beneficial effects of TRβ activation, such as reduced cholesterol and serum lipid levels, and reduced obesity due to increased cellular metabolism. See Fujitaki, JM et al., Drug Metab. Disp. 36(11)2393-403 (2008), the entire contents of which are incorporated herein by reference. However, it has been shown that even targeted TRβ agonists can result in suppression of the thyroid hormone axis (see Erion, MD, PNAS USA 104(39):15490-5 (2007), the entire contents of which are incorporated herein by reference), which can result in side effects ranging from depression and fatigue to muscle wasting and bone loss. Thus, there is a need for compositions and methods for producing activation of TRβ while reducing the suppression of the HPT axis and its associated side effects. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] WO87 / 05297

Non-licensed documents

[0008]

Non-patent document 1

Non-patent document 2

Non-patent document 3

Non-patent document 4

Non-patent document 5

Non-patent document 6

Non-patent document 7

Non-patent document 8

Non-patent document 9

Non-patent document 10

Non-patent document 11

[0009] The present disclosure provides a method of treating a condition, such as obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and thyroid cancer, in a subject in need thereof, comprising: A therapeutically effective amount of the following:

[0010] [ka]

[0011] Such a compound, During the ceremony,

[0012] G is selected from the group consisting of -O-, -S-, -S(=O)-, -S(=O)2-, -Se-, -CH2-, -CF2-, -CHF-, -C(O)-, -CH(OH)-, -CH(C1-C4 alkyl)-, -CH(C1-C4 alkoxy)-, -C(=CH2)-, -NH-, and -N(C1-C4 alkyl)-;

[0013] T is -(CR a 2) k -, -CR b =CR b -(CR a 2) n -, -(CR a 2) n -CR b =CR b -, -(CR a 2)-CR b =CR b -(CR a 2)-, -O(CR b 2)(CR a 2) n -, -S(CR b 2)(CR a 2) n -, N(R c )(CR b 2)(CR a 2) n -, N(R b )C(O)(CR a 2) n , -C(O)(CR a 2) m -, -(CR a 2) m C(O)-, -(CR a 2) C(O)(CR a 2) n , -(CR a 2) n C(O)(CR a 2) - and -C(O)NH(CRb 2)(CR a 2) p - selected from the group consisting of;

[0014] k is an integer from 1 to 4;

[0015] m is an integer from 0 to 3;

[0016] n is an integer from 0 to 2;

[0017] p is an integer from 0 to 1;

[0018] Each R a are independently hydrogen, optionally substituted -C1-C4 alkyl, halogen, -OH, optionally substituted -O-C1-C4 alkyl, -OCF3, optionally substituted -S-C1-C4 alkyl, -NR b R c , optionally substituted -C2-C4 alkenyl, and optionally substituted -C2-C4 alkynyl; However, one R a When R is bonded to C via an O, S, or N atom, other R bonded to the same C a is hydrogen or is attached via a carbon atom;

[0019] Each R b is independently selected from the group consisting of hydrogen and optionally substituted -C1-C4 alkyl;

[0020] Each R c is independently selected from the group consisting of hydrogen, and optionally substituted -C1-C4 alkyl, optionally substituted -C(O)-C1-C4 alkyl, and -C(O)H;

[0021] R 1 and R 2are each independently selected from the group consisting of halogen, optionally substituted -C1-C4 alkyl, optionally substituted -S-C1-C3 alkyl, optionally substituted -C2-C4 alkenyl, optionally substituted -C2-C4 alkynyl, -CF3, -OCF3, optionally substituted -O-C1-C3 alkyl, and cyano;

[0022] R 6 , R 7 , R 8 , and R 9 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted -C C1-C4 alkyl, optionally substituted -S-C1-C3 alkyl, optionally substituted -C2-C4 alkenyl, optionally substituted -C2-C4 alkynyl, -CF3, -OCF3, optionally substituted -O-C1-C3 alkyl, and cyano; or R 6 and T together with the carbon to which they are attached independently -NR i forming a 5- to 6-membered ring containing 0 to 2 heteroatoms selected from -, -O-, and -S-; With the proviso that when two heteroatoms are present in the ring and both heteroatoms are different from nitrogen, both heteroatoms should be separated by at least one carbon atom; X is attached to the ring by a direct bond to a ring carbon or to a ring carbon or ring nitrogen -(CR a 2) bonded by - or -C(O)-;

[0023] R i is selected from the group consisting of hydrogen, -C(O)C1-C4 alkyl, -C1-C4 alkyl, and -C1-C4-aryl;

[0024] R 3 and R 4 are independently hydrogen, halogen, -CF3, -OCF3, cyano, optionally substituted -C1 to -C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C12 Alkynyl, -SR d , -S(=O)R e , -S(=O)2R e , -S(=O)2NR f R g , -C(O)OR h , -C(O)R e , -N(R b )C(O)NR f R g , -N(R b )S(=O)2R e , -N(R b )S(=O)2NR f R g , and -NR f R g selected from the group consisting of;

[0025] Each R d is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, optionally substituted -(CR b 2) n Heterocycloalkyl, and -C(O)NR f R g selected from the group consisting of;

[0026] Each R e is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR a 2) n Aryl, optionally substituted -(CR a 2) n Cycloalkyl, and optionally substituted -(CR a 2) nheterocycloalkyl;

[0027] R f and R g Each independently represents hydrogen, optionally substituted -C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, and optionally substituted -(CR b 2) n heterocycloalkyl; or R f and R g Together, O, NR C and S, wherein the optionally substituted heterocycle is selected from the group consisting of optionally substituted -C1-C4 alkyl, -OR b , oxo, cyano, -CF3, optionally substituted phenyl, and -C(O)OR h may be substituted with 0 to 4 substituents selected from the group consisting of:

[0028] Each R h is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, and optionally substituted -(CR b 2) n heterocycloalkyl;

[0029] R 5is -OH, optionally substituted -OC1-C6 alkyl, OC(O)R e , -OC(O)OR h , -F, -NHC(O)R e , -NHS(=O)R e , -NHS(=O)2R e , -NHC(=S)NH(R h ), and -NHC(O)NH(R h ) selected from the group consisting of;

[0030] X is P(O)YR 11 Y'R 11 and;

[0031] Y and Y′ are each independently —O— or —NR v - selected from the group consisting of; When Y and Y' are -O-, R bonded to -O- 11 are independently -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH-heterocycloalkyl (wherein the cyclic moiety comprises a carbonate or thiocarbonate), optionally substituted -alkylaryl, -C(R z )2OC(O)NR z 2, -NR z -C(O)-R y , -C(R z )2-OC(O)R y , -C(R z )2-OC(O)OR y , -C(R z )2OC(O)SR y , -alkyl-SC(O)R y , -alkyl-SS-alkylhydroxy, and -alkyl-SSS-alkylhydroxy;

[0032] Y and Y' are -NR v -NR v - R bonded to 11 are independently -H, -[C(R z )2] q -COOR y, -C(R x )2COOR y , -[C(R z )2] q -C(O)SR y , and -cycloalkylene-COOR y selected from the group consisting of;

[0033] Y is -O- and Y' is NR v When R bonded to -O- is 11 are independently -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH-heterocycloalkyl (wherein the cyclic moiety comprises a carbonate or thiocarbonate), optionally substituted -alkylaryl, -C(R z )2OC(O)NR z 2, -NR z -C(O)-R y , -C(R z )2-OC(O)R y , -C(R z )2-OC(O)OR y , -C(R z )2OC(O)SR y , -alkyl-SC(O)R y , -alkyl-SS-alkylhydroxy, and -alkyl-SSS-alkylhydroxy; -NR v - R bonded to 11 are independently H, -[C(R z )2] q -COOR y , -C(R x )2COOR y , -[C(R z )2] q -C(O)SR y , and -cycloalkylene-COOR y selected from the group consisting of;

[0034] Or, Y and Y′ are independently —O— and NR v When selected from 11 and R 11are taken together as -alkyl-SS-alkyl- to form a cyclic group, or R 11 and R 11 Together with the base:

[0035] [ka]

[0036] where:

[0037] V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl;

[0038] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, where 0-1 atom is a heteroatom and the remaining atoms are carbon and are substituted by hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy bonded to carbon atoms that are 3 atoms from both Y groups bonded to phosphorus;

[0039] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, fused to aryl groups at beta and gamma positions relative to Y bonded to phosphorus;

[0040] or V and W together form a cyclic group containing 6 optionally substituted carbon atoms bonded through an additional 3 carbon atoms and substituted by one substituent selected from the group consisting of hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy bonded to one of said carbon atoms which is 3 atoms from Y bonded to phosphorus;

[0041] or Z and W together are joined through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0042] or W and W' together are joined through an additional 2-5 atoms to form a cyclic group, where 0-2 atoms are heteroatoms and the remaining atoms are carbon, and V is aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0043] Z is -CHR z OH, -CHR z O.C.(O)R y , -CHR z OC(S)R y , -CHR z OC(S)OR y , -CHR z OC(O)SR y , -CHR z OCO2R y , -OR z , -SR z , -CHR z N3, -CH2-aryl, -CH(aryl)OH, -CH(CH=CR z 2) OH, -CH(C≡CR z )OH, -R z , -NR z 2. -OCOR y , -OCO2R y , -SCOR y , -SCO2R y , -NHCOR z , -NHCO2R y , -CH2NH-aryl, -(CH2)q-OR z , and -(CH2)q-SR z selected from the group consisting of;

[0044] q is an integer 2 or 3;

[0045] Each Rz is R y and -H;

[0046] Each R y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

[0047] Each R x is independently selected from the group consisting of -H and alkyl, or R x and R x together form a cyclic alkyl group;

[0048] Each R v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl;

[0049] The present invention provides methods of treating a patient suffering from atopic dermatitis by administering one or more of the following compounds:

[0050] In some embodiments, the compound of formula I has the following proviso:

[0051] a) G is -O-, T is -CH2-, and R 1 and R 2 are bromo, and R 3 is isopropyl, R 4 is hydrogen and R 5 is -OH, then X is not P(O)(OH)2 or P(O)(OCH2CH3)2;

[0052] b) V, Z, W, and W' are not all -H; and

[0053] c) Z is -R z when at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;

[0054] d) G is -O- and T is -(CH2) 1~4 - and R 1 and R 2 are independently halogen, alkyl, and cycloalkyl; R 3 is alkyl, and R 4 is hydrogen and R 5 is -OH, then X is not -P(O)(OH)2 or -P(O)(O-lower alkyl)2; and

[0055] e) G is -O- and R 5 -NHC(O)R e , -NHS(=O) 1~2 R e , -NHC(S)NH(R b ), or -NHC(O)NH(R h ) and T is -(CH2) m -, -CH=CH-, -O(CH2) 1~2 - or -NH(CH2) 1~2 -, X is not -P(O)(OH)2 or -P(O)(OH)NH2. Preferably, the composition to be administered contains one or more of the following:

[0056] [ka]

[0057] or a pharma- ceutically acceptable salt thereof.

[0058] The methods as described herein are useful for reducing or eliminating thyroid-related side effects and side effects associated with suppression of the hypothalamic-pituitary-thyroid axis (HPT axis), while maintaining the efficacy of the compound at the same or similar levels as seen under standard daily dosing regimens. The methods described herein include utilizing strategically placed drug holidays, which surprisingly reduce the suppression of the HPT axis while maintaining the beneficial effects of the administered compound. Such drug holidays can occur every other day during the dosing schedule, or more or less frequently. In some embodiments, administration is performed daily for 1-30 days, followed by a drug holiday period for 1-30 days.

[0059] In some embodiments, the serum levels of the drug substance are allowed to fall to sub-therapeutic levels before administration of the next dose. In some other embodiments, the serum levels of the drug substance are maintained within the therapeutic window between doses. In some other embodiments, administration is performed daily with concurrent monitoring of components of the HPT axis. In some further embodiments, a drug holiday is performed whenever suppression of the HPT axis is directly observed. [Brief description of the drawings]

[0060] [Figure 1] FIG. 1 shows the effect of once daily oral administration of Compound 2 on total plasma cholesterol (TPC) levels in beagle dogs (n=4 per group) over a 14 day period. [Diagram 2] 1 shows the effect of oral administration of Compound 2 once daily for 14 days followed by alternate day administration of Compound 2 for 14 days on total plasma cholesterol (TPC) levels in beagle dogs (n=4 per group). [Diagram 3] FIG. 1 shows serum total T4 / thyroxine (tT4) levels (mean±SEM) following once-daily oral administration of Compound 2 to beagle dogs (n=4 per group). [Figure 4]FIG. 1 shows serum free T4 / thyroxine (fT4) levels (mean±SEM) following once-daily oral administration of Compound 2 to beagle dogs (n=4 per group). [Diagram 5] 1 shows serum total triiodothyronine / T3 (tT3) levels (mean ± SEM) following once-daily oral administration of Compound 2 to beagle dogs (n=4 per group). [Figure 6] 1 shows serum free triiodothyronine / T3 (fT3) levels (mean±SEM) following once-daily oral administration of Compound 2 to beagle dogs (n=4 per group). [Figure 7] FIG. 1 shows serum thyroid stimulating hormone (TSH) levels (mean±SEM) following once-daily oral administration of Compound 2 to beagle dogs (n=4 per group). [Figure 8] 1 shows the effect of oral administration of Compound 2 once daily for 14 days followed by administration of Compound 2 every other day for 14 days on serum total T4 (tT4) levels in beagle dogs (n=2 per group). [Figure 9] 1 shows the effect of oral administration of Compound 2 once daily for 14 days followed by administration of Compound 2 every other day for 14 days on serum free T4 (fT4) levels in beagle dogs (Cycle 2 + extension; n=2 per group). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0061] The present disclosure provides methods for treating fatty liver disease, non-alcoholic steatohepatitis, hyperlipidemia, dyslipidemia, hypertriglyceridemia, and other disorders associated with dysregulation of the TRβ pathway by administering a TRβ agonist. The methods of the present disclosure are further designed to prevent inhibition of the HPT axis and possible side effects associated with this inhibition.

[0062] definition The term "mammal" is used in its ordinary biological sense, and thus specifically includes human and non-human mammals, such as dogs, cats, horses, donkeys, mules, cattle, domestic buffalo, camels, llamas, alpacas, bison, yaks, goats, sheep, pigs, elk, deer, forage antelope, and non-human primates, as well as many other species.

[0063] "Subject" as used herein means a human or non-human mammal, including, but not limited to, a dog, cat, horse, donkey, mule, cow, domestic buffalo, camel, llama, alpaca, bison, yak, goat, sheep, pig, elk, deer, domestic antelope, or non-human primate, that has been treated or selected for treatment.

[0064] "Subject suspected of having" refers to a subject exhibiting one or more clinical indicators of a disease or condition. In certain embodiments, the disease or condition is obesity. In certain embodiments, the disease or condition is hyperlipidemia. In certain embodiments, the disease or condition is hypercholesterolemia. In certain embodiments, the disease or condition is diabetes. In certain embodiments, the disease or condition is non-alcoholic fatty liver disease. In certain embodiments, the disease or condition is non-alcoholic steatohepatitis. In certain embodiments, the disease or condition is atherosclerosis. In certain embodiments, the disease or condition is cardiovascular disease. In certain embodiments, the disease or condition is hypothyroidism. In certain embodiments, the disease or condition is thyroid cancer.

[0065] "Subject in need thereof" means a subject identified as in need of a therapy or treatment.

[0066] A therapeutic effect alleviates, to some extent, one or more symptoms of a disease or disorder, including curing the disease or disorder. By "curing" is meant that symptoms of active disease are eliminated. However, even after a cure is achieved, certain long-term or permanent effects of the disease may exist (such as extensive tissue damage).

[0067] As used herein, "treat", "treatment", or "treating" refers to administering a pharmaceutical composition for preventative and / or therapeutic purposes. The term "prophylactic treatment" refers to treating a patient who does not already have the relevant disease or disorder, but who is susceptible to or otherwise at risk for a particular disease or disorder, whereby the treatment reduces the likelihood that the patient will develop the disease or disorder. The term "therapeutic treatment" refers to administering treatment to a patient who already has a disease or disorder.

[0068] "Preventing" or "prevention" refers to delaying or preventing the onset, development, or progression of a condition or disease for a period of time, including weeks, months, or years.

[0069] "Amelioration" means reducing the severity of at least one indicator of a condition or disease. In certain embodiments, amelioration includes a delay or slowing of the progression of one or more indicators of a condition or disease. The severity of an indicator can be determined by subjective or objective measures known to those skilled in the art.

[0070] "Modulation" refers to a change in function or activity. In certain embodiments, modulation refers to an increase in gene expression. In certain embodiments, modulation refers to a decrease in gene expression. In certain embodiments, modulation refers to an increase or decrease in the total serum level of a particular protein. In certain embodiments, modulation refers to an increase or decrease in the free serum level of a particular protein. In certain embodiments, modulation refers to an increase or decrease in the total serum level of a particular non-protein factor. In certain embodiments, modulation refers to an increase or decrease in the free serum level of a particular non-protein factor. In certain embodiments, modulation refers to an increase or decrease in the total bioavailability of a particular protein. In certain embodiments, modulation refers to an increase or decrease in the total bioavailability of a particular non-protein factor.

[0071] "Administering" means providing a pharmaceutical agent or composition to a subject, and includes, but is not limited to, administration by a medical professional and self-administration.

[0072] Administration of the compounds disclosed herein or their pharma- ceutically acceptable salts may be by any of the accepted modes of administration of agents serving similar purposes, including, but not limited to, oral, subcutaneous, intravenous, intranasal, topical, transdermal, intraperitoneal, intramuscular, pulmonary, vaginal, rectal, or ocular administration. Oral and parenteral administration are customary when treating the indications that are the subject of the preferred embodiments.

[0073] "Parenteral administration" means administration by injection or infusion. Parenteral administration includes, but is not limited to, subcutaneous, intravenous, intramuscular, intraarterial, and intracranial administration.

[0074] "Subcutaneous administration" means administration just beneath the skin.

[0075] "Intravenous administration" means administration into a vein.

[0076] "Intra-arterial administration" means administration into an artery.

[0077] The term "agent" includes any substance, molecule, element, compound, component, or combination thereof, including, but not limited to, proteins, polypeptides, peptides or mimetics, small organic molecules, polysaccharides, polynucleotides, etc. It can be a natural product, a synthetic compound, or a chemical compound, or a combination of two or more substances.

[0078] "Drug agent" means a substance that provides a therapeutic effect when administered to a subject.

[0079] "Pharmaceutical composition" refers to a mixture of substances, including pharmaceutical agents, suitable for administration to an individual. For example, a pharmaceutical composition can include a modified oligonucleotide and a sterile aqueous solution.

[0080] "Active pharmaceutical ingredient" means the substance in a pharmaceutical composition that produces a desired effect.

[0081] The term "pharmaceutically acceptable salts" refers to salts that retain the biological effectiveness and properties of the compounds with which they are associated and are not biologically or otherwise undesirable. In many cases, the compounds herein are capable of forming acid and / or base salts due to the presence of phenolic and / or phosphonate groups or groups similar thereto. Those skilled in the art will recognize that the protonation state of any or all of these compounds may vary with the pH and ionic properties of the surrounding solution, and thus the present disclosure contemplates multiple charge states of each compound. Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like, with ammonium, potassium, sodium, calcium, and magnesium salts being particularly preferred. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine, and the like. Many such salts are known in the art, as described in WO 87 / 05297, Johnston et al., published September 11, 1987, the entire contents of which are incorporated herein by reference.

[0082] "Solvate" refers to a compound formed by the interaction of a solvent with EPI, its metabolites, or salts. Suitable solvates are pharma- ceutically acceptable solvates, including hydrates.

[0083] The useful compounds as described above can be formulated into pharmaceutical compositions for use in treating these conditions.Standard pharmaceutical formulation techniques are used, such as those disclosed in Remington's The Science and Practice of Pharmacy, 21st Edition, Lippincott Williams & Wilkins (2005), the entirety of which is incorporated herein by reference.Thus, some embodiments include pharmaceutical compositions comprising: (A) a safe and therapeutically effective amount of a compound as described herein, or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

[0084] The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, diluents, emulsifiers, binders, buffers, dispersion media, coating agents, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, or any other compounds known to those skilled in the art to be useful in preparing pharmaceutical formulations. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in therapeutic compositions is contemplated. Supplementary active agents can also be incorporated into the composition. In addition, various adjuvants as are commonly used in the art can be included. These and other such compounds are described in the literature, for example, in the Merck Index, Merck & Company, Rahway, NJ. A discussion of the inclusion of various ingredients in pharmaceutical compositions is described, for example, in Gilman et al. (eds.) (1990); Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Edition, Pergamon Press.

[0085] Some examples of substances which may serve as pharma- ceutically acceptable carriers or components thereof are sugars such as lactose, glucose, and sucrose; starches such as corn starch, potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and methylcellulose; flour tragacanth; malt; gelatin; talc; solid lubricants such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and theobroma oil; polyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers such as TWEENS; wetting agents such as sodium lauryl sulfate; colorants; flavorings; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffers.

[0086] The choice of a pharma- ceutically acceptable carrier to be used in conjunction with the present compounds is determined by the way the compound is to be administered.

[0087] The compositions described herein are preferably provided in unit dosage form. As used herein, a "unit dosage form" is a composition that contains an amount of a compound suitable for administration to a subject in a single dose, according to good medical practice. However, the preparation of a single dosage form or unit dosage form does not mean that the dosage form is administered once per day or once per course of treatment. A unit dosage form may contain a single daily dose amount, or may contain a fractional divided dose amount in which several unit dosage forms are administered over the course of a day to satisfy a daily dose. According to the present disclosure, a unit dosage form may be administered more or less frequently than once per day, and may be administered more than once per course of treatment. Such dosage forms may be administered in any manner consistent with their formulation, including orally, parenterally, and may be administered as an infusion over a period of time (e.g., from about 30 minutes to about 2-6 hours). Although single dose administration is specifically contemplated, compositions administered according to the methods described herein may also be administered as a continuous infusion or via an implantable infusion pump.

[0088] The methods described herein can utilize any of a variety of suitable forms for a variety of administration routes, such as oral, nasal, rectal, topical (including transdermal), intraocular, intracerebral, intracranial, intrathecal, intraarterial, intravenous, intramuscular, or other parenteral routes of administration. Those skilled in the art will recognize that oral and nasal compositions include compositions administered by inhalation and made using available methodologies. Depending on the particular route of administration desired, a variety of pharmaceutically acceptable carriers well known in the art can be used. Pharmaceutically acceptable carriers include, for example, solid or liquid fillers, diluents, hydrotropes, surfactants, and encapsulating materials. Optional pharmaceutically active materials may be included that do not substantially interfere with the activity of the compound. The amount of carrier used with the compound is sufficient to provide a practical amount of the material for administration per unit dose of the compound. Techniques and compositions for making dosage forms useful in the methods described herein are described in the following references, all of which are incorporated herein by reference: Modern Pharmaceutics, 4th Edition, Chapters 9 and 10 (Banker & Rhodes, eds., 2002); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1989); and Ansel, Introduction to Pharmaceutical Dosage Forms, 8th Edition (2004).

[0089] A variety of oral dosage forms can be used, including solid forms such as tablets, capsules, granules, and bulk powders. Tablets can be compressed, tablet triturated, enteric coated, sugar coated, film coated, or multiple compressed, containing appropriate binders, lubricants, diluents, disintegrants, colorants, flavorings, flow inducers, and melting agents. Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and / or suspensions reconstituted from non-effervescent granules, containing appropriate solvents, preservatives, emulsifiers, suspending agents, diluents, sweeteners, melting agents, colorants, and flavorings.

[0090] Pharmaceutically acceptable carriers suitable for preparing unit dosage forms for oral administration are well known in the art. Tablets typically contain conventional pharma- ceutically compatible adjuvants such as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose, and cellulose; binders, such as starch, gelatin, sucrose; disintegrants, such as starch, alginic acid, croscarmellose; and lubricants, such as magnesium stearate, stearic acid, microcrystalline cellulose, carboxymethylcellulose, talc. Tablets may also contain solubilizers or emulsifiers, such as poloxamer, Cremophor / Kolliphor® / Lutrol®, methylcellulose, hydroxypropylmethylcellulose, or others known in the art. Glidants, such as silicon dioxide, can be used to improve the flow properties of the powder mixture. Coloring agents, such as FD&C dyes, can be added for appearance. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint, and fruit flavors, are useful adjuvants for chewable tablets. Capsules typically contain one or more solid diluents as disclosed above. The selection of carrier components depends on secondary considerations such as taste, cost, and storage stability, and can be readily made by one skilled in the art.

[0091] Oral (PO) compositions also include solutions, emulsions, suspensions, etc. Pharmaceutically acceptable carriers suitable for preparing such compositions are well known in the art. Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol, and water. For suspensions, typical suspending agents include methylcellulose, sodium carboxymethylcellulose, AVICEL RC-591, tragacanth, and sodium alginate; typical wetting agents include lecithin and polysorbate 80, typical preservatives include methylparaben and sodium benzoate. Oral liquid compositions may also include one or more components such as sweeteners, flavoring agents, and coloring agents disclosed above.

[0092] Such compositions may also be coated by conventional methods, typically with a pH- or time-dependent coating, so that the compound is released in the digestive tract near the desired topical application, or at various times to extend the desired effect. Such dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate, ethylcellulose, Eudragit coatings, waxes, and shellac.

[0093] The compositions described herein may optionally include other pharmaceutical actives.

[0094] Other compositions useful for achieving the systemic delivery of the compound include sublingual, buccal and nasal dosage forms.Such compositions typically include one or more of the following: soluble filler material such as sucrose, sorbitol and mannitol; binder such as gum acacia, microcrystalline cellulose, carboxymethylcellulose, hydroxypropylmethylcellulose.The glidant, lubricant, sweetener, colorant, antioxidant and flavoring agent disclosed above can also be included.

[0095] Liquid compositions formulated for topical ophthalmic use are formulated so that they can be administered locally to the eye. Comfort can be maximized as much as possible, although sometimes formulation considerations (e.g., drug stability) may require suboptimal comfort. If comfort cannot be maximized, the liquid can be formulated to be acceptable to patients for topical ophthalmic use. Furthermore, ophthalmically acceptable liquids may be packaged for single use or may contain preservatives to prevent contamination over multiple uses.

[0096] For ophthalmic use, solutions or medicaments are often prepared using saline as the primary vehicle. Ophthalmic solutions are preferably maintained at a comfortable pH using an appropriate buffer system. The formulations may also contain conventional pharma- ceutically acceptable preservatives, stabilizers, and surfactants.

[0097] Preservatives that can be used in the pharmaceutical compositions disclosed herein include, but are not limited to, benzalkonium chloride, PHMB, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate. Useful surfactants are, for example, Tween 80. Similarly, various useful vehicles can be used in the ophthalmic formulations disclosed herein. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropylmethylcellulose, poloxamer, carboxymethylcellulose, hydroxyethylcellulose, and purified water.

[0098] Tonicity agents may be added as necessary or convenient, including, but not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity agent.

[0099] Various buffers and means for adjusting pH can be used as long as the resulting formulation is ophthalmologically acceptable. For many compositions, the pH will be 4 to 9. Thus, buffers include acetate buffers, citrate buffers, phosphate buffers, and borate buffers. If necessary, the pH of these formulations can be adjusted using an acid or base.

[0100] Ophthalmically acceptable antioxidants include, but are not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, and butylated hydroxytoluene.

[0101] Another excipient component that may be included in the ophthalmic formulation is a chelating agent. A useful chelating agent is edetate disodium, although other chelating agents may be used in place of or in conjunction therewith.

[0102] For topical use, including transdermal administration, creams, ointments, gels, solutions, suspensions, etc., containing the compounds disclosed herein are used. Topical formulations may generally include a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.

[0103] For intravenous administration, the compounds and compositions described herein can be dissolved or dispersed in a pharma- ceutically acceptable diluent, such as saline or dextrose solution. Suitable excipients can be included to achieve the desired pH, including, but not limited to, NaOH, sodium carbonate, sodium acetate, HCl, and citric acid. In various embodiments, the pH of the final composition ranges from 2 to 8, or preferably 4 to 7. Antioxidant excipients include sodium bisulfite, acetone sodium bisulfite, sodium formaldehyde, sulfoxylates, thiourea, and EDTA. Other non-limiting examples of suitable excipients found in the final intravenous composition include sodium or potassium phosphate, citric acid, tartaric acid, gelatin, and carbohydrates, such as dextrose, mannitol, and dextran. Further acceptable excipients are described in Powell et al., Compendium of Excipients for Parenteral Formulations, PDA J Pharm Sci and Tech 1998, 52 238-311 and Nema et al., Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions, PDA J Pharm Sci and Tech 2011, 65 287-332, the entire contents of which are incorporated herein by reference. Antimicrobial agents may also be included to achieve a bacteriostatic or fungistatic solution, including, but not limited to, phenylmercuric nitrate, thimerosal, benzethonium chloride, benzalkonium chloride, phenol, cresol, and chlorobutanol.

[0104] Compositions for intravenous administration may be provided to the caregiver in another solid form that is reconstituted with a suitable diluent, such as sterile water, saline, or dextrose in water, immediately prior to administration. In other embodiments, the compositions are provided in a solution ready for parenteral administration. In yet other embodiments, the compositions are provided in a solution that is further diluted prior to administration. In embodiments involving administration of a combination of a compound described herein with another agent, the combination may be provided to the caregiver as a mixture, and the caregiver may mix the two agents prior to administration, or the two agents may be administered separately.

[0105] The actual unit dose of the active compounds described herein will depend on the specific compound and the condition to be treated. In some embodiments, the dose can be from about 0.01 mg / kg to about 120 mg / kg body weight or more, from about 0.05 mg / kg or less to about 70 mg / kg, from about 0.1 mg / kg to about 50 mg / kg body weight, from about 1.0 mg / kg to about 10 mg / kg body weight, from about 5.0 mg / kg to about 10 mg / kg body weight, or from about 10.0 mg / kg to about 20.0 mg / kg body weight. In some embodiments, the dose can be less than 100 mg / kg, 90 mg / kg, 80 mg / kg, 70 mg / kg, 60 mg / kg, 50 mg / kg, 40 mg / kg, 30 mg / kg, 25 mg / kg, 20 mg / kg, 10 mg / kg, 7.5 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2.5 mg / kg, 1 mg / kg, 0.5 mg / kg, 0.1 mg / kg, 0.05 mg / kg, or 0.005 mg / kg body weight. In some embodiments, the actual unit dose is 0.05, 0.07, 0.1, 0.3, 1.0, 3.0, 5.0, 10.0, or 25.0 mg / kg body weight. Thus, for administration to a 70 kg individual, the dosage range would be about 0.1 mg to about 70 mg, about 1 mg to about 50 mg, about 0.5 mg to about 10 mg, about 1 mg to about 10 mg, about 2.5 mg to about 30 mg, about 35 mg or less to about 700 mg or more, about 7 mg to about 600 mg, about 10 mg to about 500 mg, about 20 mg to about 300 mg, or about 200 mg to about 2000 mg. In some embodiments, the actual unit dose is 5 mg. In some embodiments, the actual unit dose is 10 mg. In some embodiments, the actual unit dose is 25 mg. In some embodiments, the actual unit dose is 250 mg or less. In some embodiments, the actual unit dose is 100 mg or less. In some embodiments, the actual unit dose is 70 mg or less. In some embodiments, the actual unit dose is 5 mg.

[0106] As used herein, a "loading dose" refers to an initial dose of a compound that is higher than subsequent doses.

[0107] As used herein, a "maintenance dose" refers to a subsequent dose that follows a loading dose and occurs later in time than the loading dose. Those skilled in the art will understand that the dosage form or mode of administration of the maintenance dose may be different from that used for the loading dose. In any of the embodiments disclosed herein, the maintenance dose may include, but is not limited to, administration of a unit dosage form at any administration schedule contemplated herein, including once a month or multiple times a month, once every other week or multiple times every two weeks, once or multiple times a week, daily or multiple times a day. It is contemplated within the scope of this disclosure that a rest period may be incorporated into the administration period of the maintenance dose. Such a rest period may occur immediately after administration of the loading dose or at any time during the administration period of the maintenance dose. As used herein, the administration period of the maintenance dose may be referred to as the "maintenance phase" of the treatment period.

[0108] As used herein, "mode of administration" refers to the means by which a compound is administered to a subject. As used herein, "mode of administration" includes the dosage form (e.g., tablet, powder, solution, suspension, emulsion, aerosol, etc.) and the mechanism by which the dosage form is applied to a subject (e.g., by injection, such as subcutaneous, intramuscular, intraperitoneal, intravenous, or intraarterial; topical, such as cream, lotion, or patch; oral, such as pill, solution, oral suspension, buccal film, or mouthwash; intranasal, such as nasal aerosol, powder, or spray; or intraocular, such as eye drops). As used herein, "mode of administration" also includes the dose, dosage, and administration schedule by which a compound is administered to a subject.

[0109] In some embodiments, the administration regimen includes administering a loading dose followed by a maintenance dose. In some embodiments, the loading dose is 300 mg or less, 250 mg or less, 200 mg or less, 150 mg or less, or 100 mg or less. In some embodiments, the maintenance dose is 300 mg or less, 200 mg or less, 100 mg or less, 50 mg or less, 40 mg or less, 25 mg or less, 10 mg or less, 5 mg or less, or 1 mg or less.

[0110] In some embodiments, the loading dose is administered over a one day period. In some embodiments, the loading dose is administered over a two day period. In some embodiments, the loading dose is administered over a three day period. In some embodiments, the loading dose is administered over a four day period. In some embodiments, the loading dose is administered over a five, six, or seven day period. In some embodiments, the loading dose is administered over a period of eight to fourteen days or less. In some embodiments, the loading dose is administered over a fourteen day period.

[0111] As used herein, "treatment period" refers to the time period beginning with administration of the first dose and ending with administration of the final dose, such period being determined by one skilled in the art of treating diseases in which TRβ is involved, including, but not limited to, hyperlipidemia, hypercholesterolemia, NASH and NAFLD, with reference to the condition and health of the subject being treated therefor.

[0112] As used herein, a "drug holiday" refers to a period of 24 hours or more during which no dose is administered to a subject or a reduced dose is administered to a subject. As used herein, a "reduced dose" refers to a dose that is less than the total daily dose to be administered to a subject.

[0113] As used herein, the term "hypothalamic-pituitary-thyroid axis" or "HPT axis" refers to a series of neuroendocrine pathways, signals, and molecules involved in the regulation of metabolism. As used herein, "HPT axis" further refers to any molecule involved in the regulation, modification, or response to thyroid hormones. Representative components of the HPT axis include triiodothyronine (T3), thyroxine (T4), iodothyronine, thyrotropin-releasing hormone (TRH), and thyroid-stimulating hormone (TSH).

[0114] The term "alkyl" refers to a straight or branched chain or cyclic hydrocarbon group containing only a single carbon-carbon bond. Representative examples include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, cyclobutyl, pentyl, cyclopentyl, hexyl, and cyclohexyl, all of which may be optionally substituted. An alkyl group is any group that is C1-C6. 12 It is.

[0115] The term "aryl" refers to an aromatic group having 5 to 14 ring atoms and at least one ring having a conjugated pi electron system, and includes carbocyclic aryl, heterocyclic aryl, and biaryl groups, all of which may be optionally substituted.

[0116] Carbocyclic aryl groups are groups having 6 to 14 ring atoms in which the ring atoms on the aromatic ring are carbon atoms. Carbocyclic aryl groups include monocyclic carbocyclic aryl groups and polycyclic or fused compounds such as optionally substituted naphthyl groups.

[0117] Heterocyclic aryl or heteroaryl groups are groups having 5 to 14 ring atoms, with 1 to 4 heteroatoms being ring atoms in an aromatic ring, and the remaining ring atoms being carbon atoms. Suitable heteroatoms include oxygen, sulfur, nitrogen, and selenium. Suitable heteroaryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolyl, pyridyl-N-oxide, pyrimidyl, pyrazinyl, imidazolyl, and the like, all of which may be optionally substituted.

[0118] The term "biaryl" refers to an aryl group having 5 to 14 atoms containing more than one aromatic ring, including both fused ring systems and aryl groups substituted with other aryl groups. Such groups may be optionally substituted. Suitable biaryl groups include naphthyl and biphenyl.

[0119] The term "optionally substituted" or "substituted" refers to lower alkyl, lower aryl, lower aralkyl, lower cyclic alkyl, lower heterocycloalkyl, hydroxy, lower alkoxy, lower aryloxy, perhaloalkoxy, aralkoxy, lower heteroaryl, lower heteroaryloxy, lower heteroarylalkyl, lower heteroaralkoxy, azido, amino, halo, lower alkylthio, oxo, lower acylalkyl, lower carboxyester, carboxyl, -carboxamido, nitro, lower acyloxy, lower aminoalkyl, Includes groups substituted by 1 to 6 substituents independently selected from lower alkylaminoaryl, lower alkylaryl, lower alkylaminoalkyl, lower alkoxyaryl, lower arylamino, lower aralkylamino, sulfonyl, lower carboxamidoalkylaryl, lower carboxamidoaryl, lower hydroxyalkyl, lower haloalkyl, lower alkylaminoalkylcarboxy-, lower aminocarboxamidoalkyl-, cyano, lower alkoxyalkyl, lower perhaloalkyl, and lower arylalkyloxyalkyl.

[0120] "Substituted aryl" and "substituted heteroaryl" refer to aryl and heteroaryl groups substituted with one to three substituents selected from the group consisting of lower alkyl, lower alkoxy, lower perhaloalkyl, halo, hydroxy, and amino.

[0121] The term "-aralkyl" refers to an alkylene group substituted with an aryl group. Suitable aralkyl groups include benzyl, picolyl, and the like, and may be optionally substituted. "Heteroarylalkyl" refers to an alkylene group substituted with a heteroaryl group.

[0122] The term "alkylaryl-" refers to an aryl group substituted with an alkyl group. "Lower alkylaryl-" refers to a group in which the alkyl is lower alkyl.

[0123] The term "lower" as referred to herein with respect to organic groups or compounds is defined to contain, for example, 10 or fewer carbon atoms, in one embodiment 6 or fewer carbon atoms, and in another embodiment 1 to 4 carbon atoms. Such groups may be linear, branched, or cyclic.

[0124] The term "cyclic alkyl" or "cycloalkyl" refers to an alkyl group that is cyclic of 3 to 10 carbon atoms, and in one embodiment 3 to 6 carbon atoms. Suitable cyclic groups include norbornyl and cyclopropyl. Such groups may be optionally substituted.

[0125] The terms "heterocycle", "heterocyclealkyl", or "heterocycloalkyl" refer to cyclic groups of 3 to 10 atoms, in one embodiment 3 to 6 atoms including at least one heteroatom, and in further embodiments 1 to 3 heteroatoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen. Heterocyclic groups may be attached through a nitrogen or through a carbon atom in the ring. Heterocyclic alkyl groups include unsaturated cyclic, fused cyclic, and spirocyclic groups. Suitable heterocyclic groups include pyrrolidinyl, morpholino, morpholinoethyl, and pyridyl.

[0126] The terms "arylamino" (a) and "aralkylamino" (b) each refer to the group -NRR', where (a) R is aryl and R' is hydrogen, alkyl, aralkyl, heterocycloalkyl, or aryl, and (b) R is aralkyl and R' is hydrogen, aralkyl, aryl, alkyl, or heterocycloalkyl, respectively.

[0127] The term "acyl" refers to -C(O)R, where R is alkyl, heterocycloalkyl, or aryl.

[0128] The term "carboxy ester" refers to -C(O)OR, where R is alkyl, aryl, aralkyl, cyclic alkyl, or heterocycloalkyl, all optionally substituted.

[0129] The term "carboxyl" refers to -C(O)OH.

[0130] The term "oxo" refers to =O in an alkyl or heterocycloalkyl group.

[0131] The term "amino" refers to -NRR', where R and R' are independently selected from hydrogen, alkyl, aryl, aralkyl, and heterocycloalkyl, all of which except H are optionally substituted, and R and R' can form a cyclic ring system.

[0132] The term "-carboxylamide" refers to -CONR2, where each R is independently hydrogen or alkyl.

[0133] The term "-sulfonylamido" or "-sulfonylamido" refers to -S(=O)2NR2, where each R is independently hydrogen or alkyl.

[0134] The term "halogen" or "halo" refers to -F, -Cl, -Br, and -I.

[0135] The term "alkylaminoalkylcarboxy" refers to the group alkyl-NR-alk-C(O)-O-, where "alk" is an alkylene group and R is H or lower alkyl.

[0136] The terms "sulphonyl" or "sulfonyl" refer to -SO2R, where R is H, alkyl, aryl, aralkyl, or heterocycloalkyl.

[0137] The term “sulphonate” or “sulfonate” refers to —SO2OR, where R is —H, alkyl, aryl, aralkyl, or heterocycloalkyl.

[0138] The term "alkenyl" refers to an unsaturated group having 2 to 12 atoms and containing at least one carbon-carbon double bond, including straight-chain, branched-chain and cyclic groups. Alkenyl groups may be optionally substituted. Suitable alkenyl groups include allyl. "1-alkenyl" refers to an alkenyl group in which the double bond is between the first and second carbon atoms. When the 1-alkenyl group is attached to another group, for example, when it is a W substituent attached to a cyclic phosphonate, it is attached to the first carbon.

[0139] The term "alkynyl" refers to an unsaturated group having 2 to 12 atoms and containing at least one carbon-carbon triple bond, including straight-chain, branched-chain and cyclic groups. Alkynyl groups may be optionally substituted. Suitable alkynyl groups include ethynyl. "1-alkynyl" refers to an alkynyl group in which the triple bond is between the first and second carbon atoms. When the 1-alkynyl group is bonded to another group, for example, when it is a W substituent that is bonded to a cyclic phosphonate, it is bonded to the first carbon.

[0140] The term "alkylene" refers to a divalent straight-chain, branched-chain, or cyclic saturated aliphatic group. In one embodiment, the alkylene group contains 10 or fewer atoms. In another embodiment, the alkylene chain contains 6 or fewer atoms. In a further embodiment, the alkylene group contains 4 or fewer atoms. The alkylene group may be straight-chain, branched, or cyclic.

[0141] The term “acyloxy” refers to an ester group —OC(O)R, where R is H, alkyl, alkenyl, alkynyl, aryl, aralkyl, or heterocycloalkyl.

[0142] The term "aminoalkyl-" refers to the group NR2-alk-, where "alk" is an alkylene group and R is selected from -H, alkyl, aryl, aralkyl, and heterocycloalkyl.

[0143] The term "alkylaminoalkyl-" refers to the group alkyl-NR-alk- where each "alk" is an independently selected alkylene and R is H or lower alkyl. "Lower alkylaminoalkyl-" refers to the group in which the alkyl and alkylene groups are lower alkyl and alkylene, respectively.

[0144] The term "arylaminoalkyl-" refers to the group aryl-NR-alk- where "alk" is an alkylene group and R is -H, alkyl, aryl, aralkyl, or heterocycloalkyl. In "lower arylaminoalkyl-", the alkylene group is lower alkylene.

[0145] The term "alkylaminoaryl-" refers to the group alkyl-NR-aryl- where "aryl" is a divalent group and R is -H, alkyl, aralkyl, or heterocycloalkyl. In "lower alkylaminoaryl-", the alkyl group is lower alkyl.

[0146] The term "alkoxyaryl-" refers to an aryl group substituted with an alkyloxy group. In "lower alkyloxyaryl-", the alkyl group is lower alkyl.

[0147] The term "aryloxyalkyl-" refers to an alkyl group substituted with an aryloxy group.

[0148] The term "aralkyloxyalkyl-" refers to the group aryl-alk-O-alk- where "alk-" is an alkylene group. "Lower aralkyloxyalkyl-" refers to such groups where the alkylene group is lower alkylene.

[0149] The term "alkoxy-" or "alkyloxy-" refers to the group alkyl-O-.

[0150] The term "alkoxyalkyl-" or "alkyloxyalkyl-" refers to the group alkyl-O-alk-, where "alk" is an alkylene group. In "lower alkoxyalkyl-", each alkyl and alkylene is a lower alkyl and alkylene, respectively.

[0151] The terms "alkylthio-" and "alkylthio-" refer to the group alkyl-S-.

[0152] The term "alkylthioalkyl-" refers to the group alkyl-S-alk-, where "alk" is an alkylene group. In "lower alkylthioalkyl-", each alkyl and alkylene is a lower alkyl and alkylene, respectively.

[0153] The term "alkoxycarbonyloxy-" refers to alkyl-OC(O)-O-.

[0154] The term "aryloxycarbonyloxy-" refers to aryl-OC(O)-O-.

[0155] The term "alkylthiocarbonyloxy-" refers to alkyl-SC(O)-O-.

[0156] The term "amide" refers to NR2-C(O)-, RC(O)-NR 1 -, NR2-S(=O)2- and RS(=O)2-NR 1 It refers to an NR2 group adjacent to an acyl or sulfonyl group such as in -, where R and R' include -H, alkyl, aryl, aralkyl, and heterocycloalkyl.

[0157] The term "carboxamide" refers to NR-C(O)- and RC(O)-NR 1 where R and R' include -H, alkyl, aryl, aralkyl, and heterocycloalkyl. This term does not include urea, -NR-C(O)-NR-.

[0158] The term "sulphonamido" or "sulfonamido" refers to NR2-S(=O)2- and RS(=O)2-NR 1 where R and R' include -H, alkyl, aryl, aralkyl, and heterocycloalkyl. This term does not include sulfonylureas, -NR-S(-O)2-NR-.

[0159] The terms “carboxamidoalkylaryl” and “carboxamidoaryl” refer to aryl-alk-NR 1 -C(O), and ar-NR 1 -C(O)-alk-, where "ar" is aryl, "alk" is alkylene, and R 1 and R includes H, alkyl, aryl, aralkyl, and heterocycloalkyl.

[0160] The terms “sulfonamidoalkylaryl” and “sulfonamidoaryl” refer to aryl-alk-NR 1 -S(=O)2- and ar-NR 1 -S(-O)-, where "ar" is aryl, "alk" is alkylene, and R 1 and R includes -H, alkyl, aryl, aralkyl, and heterocycloalkyl.

[0161] The term "hydroxyalkyl" refers to an alkyl group substituted with one -OH.

[0162] The term "haloalkyl" refers to an alkyl group substituted with a halo.

[0163] The term "cyano" refers to -C≡N.

[0164] The term "nitro" refers to --NO.

[0165] The term "acylalkyl" refers to alkyl-C(O)-alk-, where "alk" is alkylene.

[0166] The term "aminocarboxamidoalkyl-" refers to the group NR-C(O)-N(R)-alk-, where R is an alkyl group or H, and "alk" is an alkylene group. "Lower aminocarboxamidoalkyl-" refers to such groups where "alk" is lower alkylene.

[0167] The term "heteroarylalkyl" refers to an alkylene group substituted with a heteroaryl group.

[0168] The term "perhalo" refers to a group in which all C-H bonds are replaced with C-halo bonds on an aliphatic or aryl group. Suitable perhaloalkyl groups include -CF3 and -CFCl2.

[0169] The term "carboxylic acid moiety" refers to compounds having a carboxylic acid group (-COOH), and their salts, carboxylic acid esters, or carboxylic acid substitutes. Suitable carboxylic acid substitutes include tetrazole groups, hydroxamic acid groups, thiazolidinedione groups, acylsulfonamide groups, and 6-azauracil, and prodrugs thereof. Phosphonic acids and their prodrugs are not within the scope of carboxylic acid substitutes.

[0170] [Table 1A]

[0171] [Table 1B]

[0172] Table 1 provides definitions of common abbreviations in the art as used in the embodiments and examples described herein.

[0173] As used herein, "suppression of the HPT axis" refers to a reduction in the circulating levels of any component of the HPT axis, particularly triiodothyronine (T3), thyroxine (T4), iodothyronine, thyrotropin-releasing hormone (TRH), and thyroid-stimulating hormone (TSH), either individually, in any combination, or collectively. In some embodiments, suppression of the HPT axis includes a reduction in the circulating serum levels of triiodothyronine (T3), thyroxine (T4), iodothyronine, thyrotropin-releasing hormone (TRH), or thyroid-stimulating hormone (TSH) by at least 5%. In some embodiments, suppression of the HPT axis includes a reduction in the circulating serum levels of triiodothyronine (T3), thyroxine (T4), iodothyronine, thyrotropin-releasing hormone (TRH), or thyroid-stimulating hormone (TSH) by at least 10%. In some embodiments, inhibition of the HPT axis comprises at least a 20% reduction in circulating serum levels of triiodothyronine (T3), thyroxine (T4), iodothyronine, thyrotropin-releasing hormone (TRH), or thyroid-stimulating hormone (TSH). In some embodiments, inhibition of the HPT axis comprises at least a 30%, 40%, 50%, or 60% reduction in circulating serum levels of triiodothyronine (T3), thyroxine (T4), iodothyronine, thyrotropin-releasing hormone (TRH), or thyroid-stimulating hormone (TSH). In some embodiments, inhibition of the HPT axis comprises a greater than 60% reduction in circulating serum levels of triiodothyronine (T3), thyroxine (T4), iodothyronine, thyrotropin-releasing hormone (TRH), or thyroid-stimulating hormone (TSH).

[0174] In some embodiments, inhibition of the HPT axis comprises at least a 5% reduction in free triiodothyronine (fT3) or free thyroxine (fT4) levels. In some embodiments, inhibition of the HPT axis comprises at least a 10% reduction in free triiodothyronine (fT3) or free thyroxine (fT4) levels. In some embodiments, inhibition of the HPT axis comprises at least a 20% reduction in free triiodothyronine (fT3) or free thyroxine (fT4) levels. In some embodiments, inhibition of the HPT axis comprises at least a 30%, 40%, 50%, or 60% reduction in free triiodothyronine (fT3) or free thyroxine (fT4) levels. In some embodiments, inhibition of the HPT axis comprises more than a 60% reduction in free triiodothyronine (fT3) or free thyroxine (fT4) levels.

[0175] In some embodiments, inhibition of the HPT axis comprises at least a 5% reduction in total triiodothyronine (tT3) or total thyroxine (tT4) levels. In some embodiments, inhibition of the HPT axis comprises at least a 10% reduction in total triiodothyronine (tT3) or total thyroxine (tT4) levels. In some embodiments, inhibition of the HPT axis comprises at least a 20% reduction in total triiodothyronine (tT3) or total thyroxine (tT4) levels. In some embodiments, inhibition of the HPT axis comprises at least a 30%, 40%, 50%, or 60% reduction in total triiodothyronine (tT3) or total thyroxine (tT4) levels. In some embodiments, inhibition of the HPT axis comprises more than a 60% reduction in total triiodothyronine (tT3) or total thyroxine (tT4) levels.

[0176] As contemplated herein, reduction in thyroid-related side effects includes the effect of a method of treatment in which the level of suppression of the HPT axis is less than the level of suppression seen with a daily administration of about 10 to about 40 mg / day per subject. In some embodiments, reduction in thyroid-related side effects includes the effect of a method of treatment in which the level of suppression of the HPT axis is less than the level of suppression seen with a daily administration of 40 mg / day, 30 mg / day, 20 mg / day, 15 mg / day, 10 mg / day, 5 mg / day, or 2.5 mg / day to an individual subject. In some embodiments, reduction in thyroid-related side effects includes the effect of a method of treatment in which the level of suppression of the HPT axis is less than the level of suppression seen with a daily administration of 2.5 to 35 mg / day, 2.5 to 10 mg / day, 5 to 15 mg / day, 5 mg / day, or 10 mg / day to an individual subject.

[0177] The present disclosure relates to Formula I:

[0178] [ka]

[0179] A compound of the formula: During the ceremony,

[0180] G is selected from the group consisting of -O-, -S-, -S(=O)-, -S(=O)2-, -Se-, -CH2-, -CF2-, -CHF-, -C(O)-, -CH(OH)-, -CH(C1-C4 alkyl)-, -CH(C1-C4 alkoxy)-, -C(=CH2)-, -NH-, and -N(C1-C4 alkyl)-;

[0181] T is -(CR a 2) k -, -CR b =CR b -(CR a 2) n -, -(CR a 2) n -CR b =CR b -, -(CR a 2)-CR b =CRb -(CR a 2)-, -O(CR b 2)(CR a 2) n -, -S(CR b 2)(CR a 2) n -, N(R c )(CR b 2)(CR a 2) n -, N(R b )C(O)(CR a 2) n , -C(O)(CR a 2) m -, -(CR a 2) m C(O)-, -(CR a 2) C(O)(CR a 2) n , -(CR a 2) n C(O)(CR a 2) - and -C(O)NH(CR b 2)(CR a 2) p - selected from the group consisting of;

[0182] k is an integer from 1 to 4;

[0183] m is an integer from 0 to 3;

[0184] n is an integer from 0 to 2;

[0185] p is an integer from 0 to 1;

[0186] Each R a are independently hydrogen, optionally substituted -C1-C4 alkyl, halogen, -OH, optionally substituted -O-C1-C4 alkyl, -OCF3, optionally substituted -S-C1-C4 alkyl, -NR b R c , optionally substituted -C2-C4 alkenyl, and optionally substituted -C2-C4 alkynyl; However, one R aWhen R is bonded to C via an O, S, or N atom, other R bonded to the same C a is hydrogen or is attached via a carbon atom;

[0187] Each R b is independently selected from the group consisting of hydrogen and optionally substituted -C1-C4 alkyl;

[0188] Each R c is independently selected from the group consisting of hydrogen, and optionally substituted -C1-C4 alkyl, optionally substituted -C(O)-C1-C4 alkyl, and -C(O)H;

[0189] R 1 and R 2 are each independently selected from the group consisting of halogen, optionally substituted -C1-C4 alkyl, optionally substituted -S-C1-C3 alkyl, optionally substituted -C2-C4 alkenyl, optionally substituted -C2-C4 alkynyl, -CF3, -OCF3, optionally substituted -O-C1-C3 alkyl, and cyano;

[0190] R 6 , R 7 , R 8 , and R 9 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted -C1-C4 alkyl, optionally substituted -S-C1-C3 alkyl, optionally substituted -C2-C4 alkenyl, optionally substituted -C2-C4 alkynyl, -CF3, -OCF3, optionally substituted -O-C1-C3 alkyl, and cyano; or R 6 and T together with the carbon to which they are attached independently -NR i forming a 5- to 6-membered ring containing 0 to 2 heteroatoms selected from -, -O-, and -S-; With the proviso that when two heteroatoms are present in the ring and both heteroatoms are different from nitrogen, both heteroatoms should be separated by at least one carbon atom; X is attached to the ring by a direct bond to a ring carbon or to a ring carbon or ring nitrogen -(CR a 2) bonded by - or -C(O)-;

[0191] R i is selected from the group consisting of hydrogen, -C(O)C1-C4 alkyl, -C1-C4 alkyl, and -C1-C4-aryl;

[0192] R 3 and R 4 are independently hydrogen, halogen, -CF3, -OCF3, cyano, optionally substituted -C1 to -C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, -SR d , -S(=O)R e , -S(=O)2R e , -S(=O)2NR f R g , -C(O)OR h , -C(O)R e , -N(R b )C(O)NR f R g , -N(R b )S(=O)2R e , -N(R b )S(=O)2NR f R g , and -NR f R g selected from the group consisting of;

[0193] Each R d is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, optionally substituted -(CRb 2) n Heterocycloalkyl, and -C(O)NR f R g selected from the group consisting of;

[0194] Each R e is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR a 2) n Aryl, optionally substituted -(CR a 2) n Cycloalkyl, and optionally substituted -(CR a 2) n heterocycloalkyl;

[0195] R f and R g Each independently represents hydrogen, optionally substituted -C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, and optionally substituted -(CR b 2) n heterocycloalkyl; or R f and R g Together, O, NR C and S, wherein the optionally substituted heterocycle is selected from the group consisting of optionally substituted -C1-C4 alkyl, -OR b , oxo, cyano, -CF3, optionally substituted phenyl, and -C(O)OR hmay be substituted with 0 to 4 substituents selected from the group consisting of:

[0196] Each R h is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, and optionally substituted -(CR b 2) n heterocycloalkyl;

[0197] R 5 is -OH, optionally substituted -OC1-C6 alkyl, OC(O)R e , -OC(O)OR h , -F, -NHC(O)R e , -NHS(=O)R e , -NHS(=O)2R e , -NHC(=S)NH(R h ), and -NHC(O)NH(R h ) selected from the group consisting of;

[0198] X is P(O)YR 11 Y'R 11 and;

[0199] Y and Y′ are each independently —O— or —NR v - selected from the group consisting of; When Y and Y' are -O-, R bonded to -O- 11 are independently -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH-heterocycloalkyl (wherein the cyclic moiety comprises a carbonate or thiocarbonate), optionally substituted -alkylaryl, -C(R z )2OC(O)NR z 2, -NRz -C(O)-R y , -C(R z )2-OC(O)R y , -C(R z )2-OC(O)OR y , -C(R z )2OC(O)SR y , -alkyl-SC(O)R y , -alkyl-SS-alkylhydroxy, and -alkyl-SSS-alkylhydroxy;

[0200] Y and Y' are -NR v -NR v - R bonded to 11 are independently -H, -[C(R z )2] q -COOR y , -C(R x )2COOR y , -[C(R z )2] q -C(O)SR y , and -cycloalkylene-COOR y selected from the group consisting of;

[0201] Y is -O- and Y' is NR v When R bonded to -O- is 11 are independently -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH-heterocycloalkyl (wherein the cyclic moiety comprises a carbonate or thiocarbonate), optionally substituted -alkylaryl, -C(R z )2OC(O)NR z 2, -NR z -C(O)-R y , -C(R z )2-OC(O)R y , -C(R z )2-OC(O)OR y , -C(R z )2OC(O)SR y , -alkyl-SC(O)R y, -alkyl-SS-alkylhydroxy, and -alkyl-SSS-alkylhydroxy; -NR v - R bonded to 11 are independently H, -[C(R z )2] q -COOR y , -C(R x )2COOR y , -[C(R z )2] q -C(O)SR y , and -cycloalkylene-COOR y selected from the group consisting of;

[0202] Or, Y and Y′ are independently —O— and NR v When selected from 11 and R 11 are taken together as -alkyl-SS-alkyl- to form a cyclic group, or R 11 and R 11 Together with the base:

[0203] [ka]

[0204] where:

[0205] V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl;

[0206] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, where 0-1 atom is a heteroatom and the remaining atoms are carbon and are substituted by hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy bonded to carbon atoms that are 3 atoms from both Y groups bonded to phosphorus;

[0207] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, fused to aryl groups at beta and gamma positions relative to Y bonded to phosphorus;

[0208] or V and W together form a cyclic group containing 6 optionally substituted carbon atoms bonded through an additional 3 carbon atoms and substituted by one substituent selected from the group consisting of hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy bonded to one of said carbon atoms which is 3 atoms from Y bonded to phosphorus;

[0209] or Z and W together are joined through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0210] or W and W' together are joined through an additional 2-5 atoms to form a cyclic group, where 0-2 atoms are heteroatoms and the remaining atoms are carbon, and V is aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0211] Z is -CHR z OH, -CHR z O.C.(O)R y , -CHR z OC(S)R y, -CHR z OC(S)OR y , -CHR z OC(O)SR y , -CHR z OCO2R y , -OR z , -SR z , -CHR z N3, -CH2-aryl, -CH(aryl)OH, -CH(CH=CR z 2) OH, -CH(C≡CR z )OH, -R z , -NR z 2. -OCOR y , -OCO2R y , -SCOR y , -SCO2R y , -NHCOR z , -NHCO2R y , -CH2NH-aryl, -(CH2)q-OR z , and -(CH2)q-SR z selected from the group consisting of;

[0212] q is an integer 2 or 3;

[0213] Each R z is R y and -H;

[0214] Each R y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

[0215] Each R x is independently selected from the group consisting of -H and alkyl, or R x and R x together form a cyclic alkyl group;

[0216] Each R v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl;

[0217] Methods are provided for administering compositions comprising one or more of the compounds, as well as pharma- ceutically acceptable salts thereof and prodrugs thereof, and pharma- ceutically acceptable salts of said prodrugs.

[0218] In some embodiments, the compound of formula I has the following proviso:

[0219] a) G is -O-, T is -CH2-, and R 1 and R 2 are bromo, and R 3 is isopropyl, R 4 is hydrogen and R 5 is -OH, then X is not P(O)(OH)2 or P(O)(OCH2CH3)2;

[0220] b) V, Z, W, and W' are not all -H; and

[0221] c) Z is -R z when at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;

[0222] d) G is -O- and T is -(CH2) 1~4 - and R 1 and R 2 are independently halogen, alkyl, and cycloalkyl; R 3 is alkyl, and R 4 is hydrogen and R 5 is -OH, then X is not -P(O)(OH)2 or -P(O)(O-lower alkyl)2; and

[0223] e) G is -O- and R 5 -NHC(O)R e , -NHS(=O) 1~2 R e , -NHC(S)NH(R b ), or -NHC(O)NH(R h ) and T is -(CH2) m -, -CH=CH-, -O(CH2) 1~2- or -NH(CH2) 1~2 -, X is not -P(O)(OH)2 or -P(O)(OH)NH2.

[0224] In some embodiments of Formula I:

[0225] G is selected from the group consisting of -O-, -S-, -S(=O)-, -S(=O)2-, -CH2-, -CF2-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C1-C4 alkyl)-;

[0226] T is -(CR a 2) k -, CR b =CR b -(CR a 2) n -, -(CR a 2) n -CR b =CR b , -(CR a 2)-CR b =R b (CR a 2), -O(CR b 2)(CR a 2) n -, -S(CR a 2)(CR a 2) n , -N(R b )(CR b 2)(CR a 2) n , -N(R b )C(O)(CR a 2) n -, -(CR a 2) n CH(NR b R c )-, -C(O)(CR a 2) m -, -(CR a 2) m C(O)-, -(CR a 2) C(O)(CR a 2) n -, -(CR a 2) n C(O)(CR a2) - and -C(O)NH(CR b 2)(CR a 2) selected from the group consisting of pr;

[0227] k is an integer from 0 to 4;

[0228] m is an integer from 0 to 3;

[0229] n is an integer from 0 to 2;

[0230] p is an integer from 0 to 1;

[0231] Each R a are independently hydrogen, optionally substituted -C1-C4 alkyl, halogen, -OH, optionally substituted -O-C1-C4 alkyl, -OCF3, optionally substituted -S-C1-C4 alkyl, -NR b R c , optionally substituted -C2-C4 alkenyl, and optionally substituted -C2-C4 alkynyl; However, one R a When bonded through O, S, or N, other R bonded to the same C a is hydrogen or is bonded via a carbon atom. b is independently selected from the group consisting of hydrogen, optionally substituted -C1-C4 alkyl;

[0232] Each R c is independently selected from the group consisting of hydrogen, and optionally substituted -C1-C4 alkyl, optionally substituted -C(O)-C1-C4 alkyl, and -C(O)H;

[0233] R 1 and R 2are each independently selected from the group consisting of halogen, optionally substituted -C1-C4 alkyl, optionally substituted -S-C1-C3 alkyl, optionally substituted -C2-C4 alkenyl, optionally substituted -C2-C4 alkynyl, -CF3, -OCF3, optionally substituted -O-C1-C3 alkyl, and cyano;

[0234] R 3 and R 4 are each independently hydrogen, halogen, -CF3, -OCF 3、 Cyano, optionally substituted -C1-C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR a 2) m Aryl, optionally substituted -(CR a 2) m Cycloalkyl, optionally substituted -(CR a 2) m Heterocycloalkyl, -OR d , -SR d , -S(=O)R e , -S(=O)2R e , -S(=O)2NR f R g , -C(O)NR e R g , -(O)OR h , -C(O)R e , -N(R)C(O)R e , -N(R)C(O)NR e R g , -N(R b )S(=O)2R e , -N(R b )S(=O)2NR f R g , and -NR f R g selected from the group consisting of;

[0235] Each R d is optionally substituted -C1~C 12Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, optionally substituted -(CR b 2) n Heterocycloalkyl, and -C(O)NR f R g selected from the group consisting of;

[0236] Each R e is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR a 2) n Aryl, optionally substituted -(CR e 2) n Cycloalkyl, and optionally substituted -(CR a 2) n heterocycloalkyl;

[0237] R f and R g Each independently represents hydrogen, optionally substituted -C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl and optionally substituted -CR b 2) n heterocycloalkyl; or R f and R g Together, O, NR cand S, wherein the optionally substituted heterocycle is an optionally substituted -C1-C4 alkyl, -OR b , oxo, cyano, -CF3, optionally substituted phenyl, and -C(O)OR h may be substituted with 0 to 4 substituents selected from the group consisting of:

[0238] Each R h is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, and optionally substituted -(CR b 2) n heterocycloalkyl;

[0239] R 5 is -OH, optionally substituted -OC1-C6 alkyl, -OC(O)R e , -OC(O)OR h , -F, -NHC(O)R e , -NHS(=O)R e , -NHS(=O)2R e , -NHC(=S)NH(R h ), and -NHC(O)NH(R h ) selected from the group consisting of;

[0240] X is P(O)YR 11 Y'R 11 and;

[0241] Y and Y′ are each independently —O— or —NR v - selected from the group consisting of; When Y and Y' are -O-, R bonded to -O- 11are independently -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH-heterocycloalkyl (wherein the cyclic moiety comprises a carbonate or thiocarbonate), optionally substituted -alkylaryl, -C(R z )2OC(O)NR z 2, -NR z -C(O)-R y , -C(R z )2-OC(O)R y , -C(R z )2O-C(O)OR y , -C(R z )2OC(O)SR y , -alkyl-SC(O)R y , -alkyl-SS-alkylhydroxy, and -alkyl-SSS-alkylhydroxy;

[0242] Y and Y' are -NR v -NR v - R bonded to 11 are independently -H, -[C(R z )2] q -COOR y , -C(R x )2COOR y , -[C(R z )2] q -C(O)SR y , and -cycloalkylene-COOR y selected from the group consisting of;

[0243] Y is -O- and Y' is NR v When R bonded to -O- is 11 are independently -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH-heterocycloalkyl (wherein the cyclic moiety comprises a carbonate or thiocarbonate), optionally substituted -alkylaryl, -C(R z )2OC(O)NR z 2, -NR z -C(O)-R y, -C(R z )2-OC(O)R y , -C(R z )2-OC(O)OR y , -C(R z )2OC(O)SR y , -alkyl-SC(O)R y , -alkyl-SS-alkylhydroxy, and -alkyl-SSS-alkylhydroxy; -NR v - R bonded to 11 are independently -H, -[C(R z )2] q -COOR y , -C(R x )2COOR y , -[C(R z )2] q -C(O)SR y , and -cycloalkylene-COOR y selected from the group consisting of;

[0244] Or, Y and Y′ are independently —O— and —NR v When selected from 11 and R 11 are taken together as -alkyl-SS-alkyl- to form a cyclic group, or R 11 and R 11 Together with the base:

[0245] [ka]

[0246] where:

[0247] V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl;

[0248] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, where 0-1 atom is a heteroatom and the remaining atoms are carbon and are substituted by hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy bonded to carbon atoms that are 3 atoms from both Y groups bonded to phosphorus;

[0249] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, fused to aryl groups at beta and gamma positions relative to Y bonded to phosphorus;

[0250] or V and W together form a cyclic group containing 6 optionally substituted carbon atoms bonded through an additional 3 carbon atoms and substituted by one substituent selected from the group consisting of hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy bonded to one of said carbon atoms which is 3 atoms from Y bonded to phosphorus;

[0251] or Z and W together are joined through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0252] or W and W' together are joined through an additional 2-5 atoms to form a cyclic group, where 0-2 atoms are heteroatoms and the remaining atoms are carbon, and V is aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0253] Z is -CHR z OH, -CHR z O.C.(O)R y , -CHR z OC(S)R y, -CHR z OC(S)OR y , -CHR z OC(O)SR y , -CR z OCO2R y , -OR z , -SR z , -CHR z N3, -CH2aryl, -CH(aryl)OH, -CH(CH=CR z 2) OH, -CH(C≡CR z )OH, -R z , -NR z 2. -OCOR y , -OCO2R y , -SCOR y , -SCO2R y , -NHCOR z , -NHCO2R y , -CH2NHaryl, -(CH2)q-OR z , and -(CH2)q-SR z selected from the group consisting of;

[0254] Q is an integer 2 or 3;

[0255] Each R z is R y and -H;

[0256] Each R y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

[0257] Each R x is independently selected from the group consisting of -H and alkyl, or R x and R x together form a cyclic alkyl group;

[0258] Each R y is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl;

[0259] However, under the following conditions:

[0260] a) G is -O-, T is -CH2-, and R 1 and R 2 are bromo, and R 3 is isopropyl, R 4 is hydrogen and R 5 is -H, then X is not P(O)(OH)2 or P(O)(OCH2CH3)2;

[0261] b) V, Z, W, and W' are not all -H; and

[0262] c) Z is -R z When at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl.

[0263] In another embodiment of Formula I:

[0264] G is selected from the group consisting of -O-, -S-, -S(=O)-, -S(-O)2-, -CH2-, -CF2-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C1-C4 alkyl)-;

[0265] T is -(CR a 2) k , -CR b =CR b -(CR a 2) n -, -(CR a 2) n -CR b =CR b -, -(CR a 2)-CR b =CR b -(CR a 2) -, -(CR, -(CR b 2)(CR a 2) n -, -S(CR b 2)(CR a 2) n -, N(R c )(CR b 2)(CR a2) n -, N(R)C(O)(CR a 2)-,-(CR a 2) n CH(NR b R c )-, -C(O)(CR a 2) m -, -(CR a 2) m C(O), -(CR a 2) C(O)(CR a 2) m -(CR a 2) n C(O)(CR a 2) - and -C(O)NH(CR b 2)(CR a 2) p - selected from the group consisting of;

[0266] k is an integer from 0 to 4;

[0267] m is an integer from 0 to 3;

[0268] n is an integer from 0 to 2;

[0269] p is an integer from 0 to 1;

[0270] Each R a are independently hydrogen, optionally substituted -C1-C4 alkyl, halogen, -OH, optionally substituted -O-C1-C4 alkyl, -OCF3, optionally substituted -S-C1-C4 alkyl, -NR b R c , optionally substituted -C2-C4 alkenyl, and optionally substituted -C2-C4 alkynyl; However, one R a When R is bonded to C via an O, S, or N atom, other R bonded to the same C a is hydrogen or is attached via a carbon atom;

[0271] Each R bis independently selected from the group consisting of hydrogen, optionally substituted -C1-C4 alkyl;

[0272] Each R c is independently selected from the group consisting of hydrogen, and optionally substituted -C1-C4 alkyl, optionally substituted -C(O)-C1-C4 alkyl, and -C(O)H;

[0273] R 1 and R 2 are each independently selected from the group consisting of halogen, optionally substituted -C1-C4 alkyl, optionally substituted -S-C1-C3 alkyl, optionally substituted -C2-C4 alkenyl, optionally substituted -C2-C4 alkynyl, -CF3, -OCF3, optionally substituted -O-C1-C3 alkyl, and cyano;

[0274] R 3 and R 4 are each independently hydrogen, halogen, -CF3, -OCF 3、 Cyano, optionally substituted -C1-C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR a 2) m Aryl, optionally substituted -(CR a 2) m Cycloalkyl, optionally substituted -(CR a 2) m Heterocycloalkyl, -OR d , -SR d , -S(=O)R e , -S(=O)2R e , -S(=O)2NR f R g , -C(O)NR f R g , -C(O)OR h , -C(O)R e , -N(R)C(O)R e , -N(R)C(O)NR f Rg , -N(R)S(=O)2R e , -N(R b )S(=O)2NR f R g , and -NR f R g selected from the group consisting of;

[0275] Each R d is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, optionally substituted -(CR b 2) n Heterocycloalkyl, and -C(O)NR f R g selected from the group consisting of;

[0276] Each R e is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR a 2) n Aryl, optionally substituted -(CR a 2) n Cycloalkyl, and optionally substituted -(CR a 2) selected from the group consisting of heterocycloalkyl;

[0277] R f and R g each independently represents hydrogen, optionally substituted C1-C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CRb 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, and optionally substituted -(CR b 2) n heterocycloalkyl; or R f and R g Together, O, NR c and S, wherein the optionally substituted heterocycle is selected from the group consisting of optionally substituted -C1-C4 alkyl, -OR b , oxo, cyano, -CF3, optionally substituted phenyl, and -C(O)OR h may be substituted with 0 to 4 substituents selected from the group consisting of:

[0278] Each R h is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, and optionally substituted -(CR b 2) n heterocycloalkyl;

[0279] R 5 is -OH, optionally substituted -OC1-C6 alkyl, -OC(O)R e , -OC(O)OR h , -F, -NHC(O)R e , -NHS(=O)R e , -NHS(=O)2R e , -NHC(=S)NH(R h ), and -NHC(O)NH(R h ) selected from the group consisting of;

[0280] X is P(O)YR 11 Y'R 11 and;

[0281] Y and Y′ are each independently —O— or —NR v - selected from the group consisting of; When Y and Y' are -O-, R bonded to -O- 11 are independently -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH-heterocycloalkyl (wherein the cyclic moiety comprises a carbonate or thiocarbonate), optionally substituted -alkylaryl, -C(R z )2OC(O)NR z 2, -NR z -C(O)-R y , -C(R z )2-OC(O)R y , -C(R z )2-OC(O)OR y , -C(R z )2OC(O)SR y , -alkyl-SC(O)R y , -alkyl-SS-alkylhydroxy, and -alkyl-SSS-alkylhydroxy;

[0282] Y and Y' are -NR v -NR v - R bonded to 11 are independently -H, -[C(R z )2] q -COOR y , -C(R x )2COOR y , -[C(R z )2] q -C(O)SR y , and -cycloalkylene-COOR y selected from the group consisting of;

[0283] Y is -O- and Y' is NR v When R bonded to -O- is 11are independently -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH-heterocycloalkyl (wherein the cyclic moiety comprises a carbonate or thiocarbonate), optionally substituted -alkylaryl, -C(R z )2OC(O)NR z 2, -NR z -C(O)-R y , -C(R z )2-OC(O)R y , -C(R z )2-OC(O)OR y , -C(R z )2OC(O)SR y , -alkyl-SC(O)R y , -alkyl-SS-alkylhydroxy, and -alkyl-SSS-alkylhydroxy; -NR v - R bonded to 11 are independently -H, -[C(R z )2] q -COOR y , -C(R x )2COOR y , -[C(R z )2] q -C(O)SR y , and -cycloalkylene-COOR y selected from the group consisting of;

[0284] Or, Y and Y′ are independently —O— and —NR v When selected from 11 and R 11 are taken together as -alkyl-SS-alkyl- to form a cyclic group, or R 11 and R 11 Together with the base:

[0285] [ka]

[0286] where:

[0287] V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl;

[0288] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, where 0-1 atom is a heteroatom and the remaining atoms are carbon and are substituted by hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy bonded to carbon atoms that are 3 atoms from both Y groups bonded to phosphorus;

[0289] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, fused to aryl groups at beta and gamma positions relative to Y bonded to phosphorus;

[0290] or V and W together form a cyclic group containing 6 optionally substituted carbon atoms bonded through an additional 3 carbon atoms and substituted by one substituent selected from the group consisting of hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy bonded to one of said carbon atoms which is 3 atoms from Y bonded to phosphorus;

[0291] or Z and W together are joined through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0292] or W and W' together are joined through an additional 2-5 atoms to form a cyclic group, where 0-2 atoms are heteroatoms and the remaining atoms are carbon, and V is aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0293] Z is -CHR z OH, -CHR z O.C.(O)R y , -CHR z OC(S)R y , -CHR z OC(S)OR y , -CHR z OC(O)SR y , -CHR z OCO2R y , -OR z , -SR z , -CHR z N3, -CH2aryl, -CH(aryl)OH, -CH(CH=CR z 2) OH, -CH(C≡CR z )OH, -R z , -NR z 2. -OCOR y , -OCO2R y , -SCOR y , -SCO2R y , -NHCOR z , -NHCO2R y , -CH2NHaryl, -(CH2)q-OR z , and -(CH2)q-SR z selected from the group consisting of;

[0294] q is an integer 2 or 3;

[0295] Each R z is R y and -H;

[0296] Each R y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

[0297] Each Rx is independently selected from the group consisting of -H and alkyl, or R x and R x together form a cyclic alkyl group;

[0298] Each R v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl;

[0299] provided that G is -O-, T is -CH2-, and R 1 and R 2 are bromo, and R 3 is isopropyl, R 4 is hydrogen and R 5 is -OH, then X is not P(O)(OH)2 or P(O)(OCH2CH3)2;

[0300] and pharma- ceutically acceptable salts thereof and prodrugs thereof, as well as pharma- ceutically acceptable salts of said prodrugs.

[0301] In various other embodiments of Formula I:

[0302] G is selected from the group consisting of -O-, -S-, -S(=O)-, -S(=O)2-, -CH2-, -CF2-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C1-C4 alkyl)-;

[0303] T is -(CR a 2) k -, -CR b =CR b -(CR a 2) n -, -(CR a 2) n -CR b =CR b , -(CR a 2)-CR b =CR b -(CR a 2)-, -O(CR b 2)(CRa 2) n -, -S(CR b 2)(CR a 2) n -, -N(R c )-(CR b 2)(CR a 2)-, -N(R b )C(O)(CR a 2) n -, -(CR a 2) n CH(NR b R c )-, C(O)(CR a 2) m -, -(CR a 2) m C(O)-, -(CR a 2) C(O)(CR a 2) n -, -(CR a 2) n C(O)(CR a 2) - and -C(O)NH(CR b 2)(CR a 2) p - selected from the group consisting of;

[0304] k is an integer from 0 to 4;

[0305] m is an integer from 0 to 3;

[0306] n is an integer from 0 to 2;

[0307] p is an integer from 0 to 1;

[0308] Each R a are independently hydrogen, optionally substituted -C1-C4 alkyl, halogen, -OH, optionally substituted -O-C1-C4 alkyl, -OCF3, optionally substituted -S-C1-C4 alkyl, -NR b R c , optionally substituted -C2-C4 alkenyl, and optionally substituted -C2-C4 alkynyl; However, one R aWhen R is bonded to C via an O, S, or N atom, other R bonded to the same C a is hydrogen or is attached via a carbon atom;

[0309] Each R b is independently selected from the group consisting of hydrogen and optionally substituted -C1-C4 alkyl;

[0310] Each R c is independently selected from the group consisting of hydrogen, optionally substituted -C1-C4 alkyl, optionally substituted -C(O)-C1-C4 alkyl, and -C(O)H;

[0311] R 1 and R 2 are each independently selected from the group consisting of halogen, optionally substituted -C1-C4 alkyl, optionally substituted -S-C1-C3 alkyl, optionally substituted -C2-C4 alkenyl, optionally substituted -C2-C4 alkynyl, -CF3, -OCF3, optionally substituted -O-C1-C3 alkyl, and cyano;

[0312] R 3 and R 4 are each independently hydrogen, halogen, -CF3, -OCF 3、 Cyano, optionally substituted -C1-C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR a 2) m Aryl, optionally substituted -(CR a 2) m Cycloalkyl, optionally substituted (CR a 2) m Heterocycloalkyl, -OR d , -SR d , -S(=O)R e , -S(=O)2R e , -S(=O)2R f Rg , -C(O)NR f R g , -C(O)OR h , -C(O)R e , -N(R)C(O)R e , -N(R)C(O)NR f R g , -N(R b )S(=O)2R e , -N(R b )S(=O)2NR f R g , and -NR f R g selected from the group consisting of;

[0313] Each R d is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, optionally substituted -(CR b 2) n Heterocycloalkyl, and -C(O)NR f R g selected from the group consisting of;

[0314] Each R e is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, and optionally substituted -(CR b 2) n is heterocycloalkyl;

[0315] Rf and R g Each independently represents hydrogen, optionally substituted -C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, and optionally substituted -(CR b 2) n heterocycloalkyl; or R f and R g Together, O, NR c and S, wherein the optionally substituted heterocycle is an optionally substituted -C1-C4 alkyl, -OR b , oxo, cyano, -CF3, optionally substituted phenyl, and -C(O)OR h may be substituted with 0 to 4 substituents selected from the group consisting of:

[0316] Each R h is optionally substituted -C1~C 12 Alkyl, optionally substituted -C to C 12 Alkenyl, optionally substituted -C 12 Alkynyl, optionally substituted -(CR b 2) n Aryl, optionally substituted -(CR b 2) n Cycloalkyl, and optionally substituted -(CR b 2) n heterocycloalkyl;

[0317] R 5 is -OH, optionally substituted -OC1-C6 alkyl, -OC(O)R e , -OC(O)OR h, -F, -NHC(O)R e , -NHS(=O)R e , -NHS(=O)2R e , -NHC(=S)NH(R h ), and -NHC(O)NH(R);

[0318] X is P(O)YR 11 Y'R 11 and;

[0319] Y and Y′ are each independently —O— or —NR v - selected from the group consisting of; When Y and Y' are -O-, R bonded to -O- 11 are independently -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH-heterocycloalkyl (wherein the cyclic moiety comprises a carbonate or thiocarbonate), optionally substituted -alkylaryl, -C(R z )2OC(O)NR z 2, -NR z -C(O)-R y , -C(R z )2-OC(O)R y , -C(R z )2-OC(O)OR y , -C(R z )2OC(O)SR y , -alkyl-SC(O)R y , -alkyl-SS-alkylhydroxy, and -alkyl-SSS-alkylhydroxy;

[0320] Y and Y' are -NR v -NR v - R bonded to 11 are independently -H, -[C(R z )2] q -COOR y , -C(R x )2COOR y , -[C(R z )2] q -C(O)SRy , and -cycloalkylene-COOR y selected from the group consisting of;

[0321] Y is -O- and Y' is NR v When R bonded to -O- is 11 are independently -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH-heterocycloalkyl (wherein the cyclic moiety comprises a carbonate or thiocarbonate), optionally substituted -alkylaryl, -C(R z )2OC(O)NR e 2, -NR z -C(O)-R y , -C(R z )2-OC(O)R y , -C(R z )2-OC(O)OR y , -C(R z )2OC(O)SR y , -alkyl-SC(O)R y , -alkyl-SS-alkylhydroxy, and -alkyl-SSS-alkylhydroxy; -NR v - R bonded to 11 are independently -H, -[C(R z )2] q -COOR y , -C(R x )2COOR y , -[C(R z )2] q -C(O)SR y , and -cycloalkylene-COOR y selected from the group consisting of;

[0322] Or, Y and Y′ are independently —O— and —NR v When selected from 11 and R 11 are taken together as -alkyl-SS-alkyl- to form a cyclic group, or R 11 and R 11 Together with the base:

[0323] [ka]

[0324] where:

[0325] V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl;

[0326] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, where 0-1 atom is a heteroatom and the remaining atoms are carbon and are substituted by hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy bonded to carbon atoms that are 3 atoms from both Y groups bonded to phosphorus;

[0327] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, fused to aryl groups at beta and gamma positions relative to Y bonded to phosphorus;

[0328] or V and W together form a cyclic group containing 6 optionally substituted carbon atoms bonded through an additional 3 carbon atoms and substituted by one substituent selected from the group consisting of hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy bonded to one of said carbon atoms which is 3 atoms from Y bonded to phosphorus;

[0329] or Z and W together are joined through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0330] or W and W' together are joined through an additional 2-5 atoms to form a cyclic group, where 0-2 atoms are heteroatoms and the remaining atoms are carbon, and V is aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0331] Z is -CHR z OH, -CHR z O.C.(O)R y , -CHR z OC(S)R y , -CHR z OC(S)OR y , -CHR z OC(O)SR y , -CHR z OCO2R y , -OR z , -SR z , -CHR z N3, -CH2aryl, -CH(aryl)OH, -CH(CH=CR z 2) OH, -CH(C≡CR z )OH, -R z , -NR z 2. -OCOR y , -OCO2R y , -SCOR y , -SCO2R y , -NHCOR z , -NHCO2R y , -CH2NHaryl, -(CH2)q-OR z , and -(CH2)q-SR z selected from the group consisting of;

[0332] q is an integer 2 or 3;

[0333] Each R z is R yand -H;

[0334] Each R y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

[0335] Each R x is independently selected from the group consisting of -H and alkyl, or R x and R x together form a cyclic alkyl group;

[0336] Each R v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl;

[0337] However, under the following conditions:

[0338] a) G is -O- and T is -(CH2) 0~4 - and R 1 and R 2 are independently halogen, alkyl of 1 to 3 carbons, and cycloalkyl of 3 to 5 carbons; R 3 is an alkyl of 1 to 4 carbons or a cycloalkyl of 3 to 7 carbons, and R 4 is hydrogen and R 5 is -OH, then X is not -P(O)(OH)2 or -P(O)(O-lower alkyl)2;

[0339] b) G is -O- and R 5 -NHC(O)R e , -NHS(=O) 1~2 R e , -NHC(S)NH(R h ), or -NHC(O)NH(R h ) and T is -(CH2) m -, -CH=CH-, -O(CH2) 1~2 - or -NH(CH2) 1~2 -, then X is not -P(O)(OH)2 or -P(O)(OH)NH2;

[0340] and pharma- ceutically acceptable salts thereof and prodrugs thereof, as well as pharma- ceutically acceptable salts of said prodrugs.

[0341] In one embodiment, G is -O-. In another embodiment, G is -CH2-. In yet another embodiment, G is selected from the group consisting of -O- and -CH2-. In another embodiment, G is -S-. In a further embodiment, G is -S(=O)-. In another embodiment, G is -S(=O)2-. In a further embodiment, G is -CH2-. In another embodiment, G is -CF2-. In a further embodiment, G is -CHF-. In another embodiment, G is -C(O)-. In another embodiment, G is -CH(OH)-. In a further embodiment, G is -NH-.

[0342] In another embodiment, G is -N(C1-C4 alkyl)-. In yet another embodiment, G is selected from the group consisting of -O-, -S-, and -CH2-.

[0343] In one embodiment, T is -CH2-. In another embodiment, T is -(CH2) 0~4 In another embodiment, T is -(CH2) m -, -CH=CH-, -O(CH2) 1~2 - and -NH(CH2) 1~2 In yet another embodiment, T is selected from the group consisting of (CR a 2) n , -O(CR b 2)(CR a 2) p -, -N(CR b 2)(CR a 2) p -, -S(CR b 2)(CR a 2) p -, -NR b (CO)- and -CHCH(NR c R b)-. In another embodiment, T is -CHCH(NH)-. In another embodiment, T is -N(H)C(O)-. In a further embodiment, T is -OCH-. In another embodiment, T is -CHCH-. In yet another embodiment, T is -CHCH(NH)-. In another embodiment, T is -N(H)C(O)-.

[0344] In a further embodiment, T is -(CR a 2) k In another embodiment, T is -CR b CR b -(CR a 2) n In a further embodiment, T is -(CR a 2) n -CR b =CR b In another embodiment, T is -(CR a 2)-CR b =CR b -(CR a 2) -. In a further embodiment, T is -O(CR b 2)(CR a 2) n In another embodiment, T is -S(CR b 2)(CR a 2) n In a further embodiment, T is -N(CR b 2)(CR a 2) n In another embodiment, T is -N(R b )C(O)(CR a 2) n In a further embodiment, T is -(CR e 2) n CH(NR b R c In another embodiment, T is -C(O)(CR a 2) m In a further embodiment, T is -(CR a 2) m In another embodiment, T is -(CR a 2) C(O)(CR a 2) nIn a further embodiment, T is -(CR a 2) n C(O)(CR a 2) -. In yet another embodiment, T is -C(O)NH(CR b 2)(CR a 2) p -It is.

[0345] In one embodiment, k is 0. In a further embodiment, k is 1. In a further embodiment, k is 2. In a further embodiment, k is 3. In yet another embodiment, k is 4. In one embodiment, m is 0. In a further embodiment, m is 1. In a further embodiment, m is 2. In a further embodiment, m is 3. In one embodiment, n is 0. In a further embodiment, n is 1. In a further embodiment, n is 2. In one embodiment, p is 0. In another embodiment, p is 1.

[0346] In one aspect, each R a is hydrogen, except that there is one R a When R is bonded to C through an O, S, or N atom, other R bonded to the same C a is hydrogen or is bonded via a carbon atom. a is an optionally substituted -C1-C4 alkyl, provided that one R a When R is bonded to C through an O, S, or N atom, other R bonded to the same C a is hydrogen or is attached via a carbon atom. a is a halogen, except that one R a When R is bonded to C through an O, S, or N atom, other R bonded to the same C a is hydrogen or is attached via a carbon atom. a is -OH, except that one R a When R is bonded to C through an O, S, or N atom, other R bonded to the same C a is hydrogen or is attached via a carbon atom. ais an optionally substituted -O-C1-C4 alkyl, provided that one R a When R is bonded to C through an O, S, or N atom, other R bonded to the same C a is hydrogen or is attached via a carbon atom. a is -OCF3, except for one R a When R is bonded to C through an O, S, or N atom, other R bonded to the same C a is hydrogen or is attached via a carbon atom. a is optionally substituted -S-C1-C4 alkyl, provided that one R a When R is bonded to C through an O, S, or N atom, other R bonded to the same C a is hydrogen or is attached via a carbon atom. a -NR b R c However, there is one R a When R is bonded to C through an O, S, or N atom, other R bonded to the same C a is hydrogen or is attached via a carbon atom. a is an optionally substituted -C2-C4 alkenyl, provided that one R a When R is bonded to C through an O, S, or N atom, other R bonded to the same C a is hydrogen or is attached via a carbon atom. a is an optionally substituted -C2-C4 alkynyl, provided that one R a When R is bonded to C through an O, S, or N atom, other R bonded to the same C a is hydrogen or is bonded via a carbon atom.

[0347] In one embodiment, R b is hydrogen. In a further embodiment, R b is an optionally substituted -C1-C4 alkyl.

[0348] In one embodiment, R c is hydrogen. In another embodiment, R c is optionally substituted -C1-C4 alkyl. In a further embodiment, R c is optionally substituted -C(O)-C1-C4 alkyl. c is -C(O)H.

[0349] In one embodiment, R 1 and R 2 Each is bromo. In another embodiment, R 1 and R 2 is independently selected from the group consisting of hydrogen, halogen, alkyl of 1 to 3 carbons, and cycloalkyl of 3 to 5 carbons. 1 and R 2 are independently halogen, alkyl of 1 to 3 carbons, and cycloalkyl of 3 to 5 carbons. 1 and R 2 are the same and are selected from the group consisting of halogen, -C1-C4 alkyl, -CF3, and cyano. 1 and R 2 is different and is selected from the group consisting of halogen, -C1-C4 alkyl, -CF3, and cyano. 1 and R 2 are each independently selected from the group consisting of halogen, -C1-C4 alkyl, -CF3, and cyano. 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano. 1 and R 2 Each is iodo. In one embodiment, R 1 and R 2 Each is methyl. In a further embodiment, R 1 and R 2 Each is chloro. In another embodiment, R 1 and R 2are each independently selected from the group consisting of iodo, bromo, chloro, and methyl.

[0350] In a further aspect, R 1 and R 2 Each is a halogen. 1 and R 2 Each is optionally substituted -C1-C4 alkyl. 1 and R 2 Each is optionally substituted -S-C1-C3 alkyl. 1 and R 2 Each is an optionally substituted -C2-C4 alkenyl. 1 and R 2 Each is an optionally substituted -C2-C4 alkynyl. 1 and R 2 Each is -CF3. In a further embodiment, R 1 and R 2 Each is -OCF3. In another embodiment, R 1 and R 2 Each is optionally substituted -O-C1-C3 alkyl. 1 and R 2 are each cyano.

[0351] In yet another embodiment, R 3 and R 4 Each is hydrogen. 3 and R 4 Each is halogen. In a further embodiment, R 3 and R 4 Each is -CF3. In another embodiment, R 3 and R 4 Each is -OCF3. In a further embodiment, R 3 and R 4 Each is cyano. In another embodiment, R 3 and R 4 Each of the optionally substituted -C1 to -C 12 In a further embodiment, R 3 and R 4Each of the optionally substituted -C 12 In another embodiment, R 3 and R 4 Each of the optionally substituted -C 12 In a further embodiment, R 3 and R 4 are each optionally substituted -(CR a 2) m In another embodiment, R 3 and R 4 are each optionally substituted -(CR a 2) m In a further embodiment, R 3 and R 4 are each optionally substituted -(CR a 2) n In another embodiment, R 3 and R 4 -OR d In another embodiment, R 3 and R 4 are -SR d In a further embodiment, R 3 and R 4 are -S(=O)R respectively e In another embodiment, R 3 and R 4 are -S(=O)2R e In a further embodiment, R 3 and R 4 are -S(=O)2NR f R g In another embodiment, R 3 and R 4 are -C(O)NR 9 In a further embodiment, R 3 and R 4 are -C(O)OR h In another embodiment, R 3 and R 4 are -C(O)R e In a further embodiment, R 3 and R 4 are -N(R b )C(O)R eIn another embodiment, R 3 and R 4 are -N(R)C(O)NR f R g In a further embodiment, R 3 and R 4 are -N(R)S(=O)2R respectively. e In another embodiment, R 3 and R 4 are -N(R b )S(=O)2NR f R g In a further embodiment, R 1 and R 4 are -NR f R g It is.

[0352] In one embodiment, R 4 is selected from the group consisting of hydrogen, halogen, -C1-C4 alkyl, cyano, and CF3. 4 is not hydrogen. 4 is selected from the group consisting of hydrogen and halogen. 4 is selected from the group consisting of hydrogen and iodine. 4 is hydrogen.

[0353] In another embodiment, each R d is optionally substituted -C1~C 12 In a further embodiment, each R d is optionally substituted -C2~C 12 alkenyl. In another embodiment, each R d is optionally substituted -C2~C 12 In a further embodiment, each R d is optionally replaced by -(CR b 2) n In another embodiment, each R d is optionally replaced by -(CR b 2) n In a further embodiment, each R d is optionally replaced by -(CRb 2) n In another embodiment, each R d -C(O)NR f R g It is.

[0354] In a further aspect, R e is optionally substituted -C1~C 12 In another embodiment, R e is optionally substituted -C2~C 12 In a further embodiment, R is alkenyl. a is optionally substituted -C2~C 12 In another embodiment, R e is optionally replaced by -CR a 2) n In a further embodiment, R e is optionally replaced by -(CR b 2) n In another embodiment, R e is optionally replaced by -(CR a 2) n It is a heterocycloalkyl.

[0355] In one embodiment, R f and R g Each is hydrogen. In a further embodiment, R f and R g Each of the optionally substituted -C1 to -C 12 In another embodiment, R f and R g Each of the optionally substituted -C 12 In a further embodiment, R is alkenyl. f and R g Each of the optionally substituted -C 12 In a further embodiment, R f and R g are each optionally substituted -(CR b 2) n In a further embodiment, R f and R gare each optionally substituted -(CR b 2) n In another embodiment, R f and R g are each optionally substituted -(CR b 2) n It is a heterocycloalkyl.

[0356] In a further aspect, R f and R g may together form an optionally substituted heterocycle, which may contain a second hetero group that is O. In another embodiment, R f and R g may together form an optionally substituted heterocycle, which is NR c In another embodiment, R f and R g may together form an optionally substituted heterocycle, which may contain a second hetero group that is S. In one embodiment, R f and R g may together form an unsubstituted heterocycle, which may contain a second hetero group. In another embodiment, the optionally substituted heterocycle is an optionally substituted -C1-C4 alkyl, -OR b , oxo, cyano, -CF3, optionally substituted phenyl, and -C(O)OR h In a further embodiment, the optionally substituted heterocycle is optionally substituted with one substituent selected from the group consisting of: optionally substituted -C1-C4 alkyl, -OR h , oxo, cyano, -CF3, optionally substituted phenyl, and -C(O)OR h In another embodiment, the optionally substituted heterocycle is optionally substituted with two substituents selected from the group consisting of: optionally substituted -C1-C4 alkyl, -OR b , oxo, cyano, -CF3, optionally substituted phenyl, and -C(O)OR hIn a further embodiment, the optionally substituted heterocycle is optionally substituted with three substituents selected from the group consisting of: optionally substituted -C1-C4 alkyl, -OR b , oxo, cyano, -CF3, optionally substituted phenyl, and -C(O)OR h and optionally substituted with four substituents selected from the group consisting of:

[0357] In a further aspect, R h is optionally substituted -C1~C 12 In another embodiment, R h is optionally substituted -C2~C 12 In a further embodiment, R is alkenyl. h is optionally substituted -C2~C 12 In another embodiment, R h is optionally replaced by -(CR b 2) n In a further embodiment, R h is optionally replaced by -(CR b 2) n In another embodiment, R h is optionally replaced by -(CR b 2) n It is a heterocycloalkyl.

[0358] In one embodiment, R 5 is -OH. In another embodiment, R 5 -OH, -OC(O)R e , -OC(O)OR h , -F, and -NHC(O)R e In a further embodiment, R 5 is -OH and -OC(O)R e In a further embodiment, R 5 is an optionally substituted -OC1-C6 alkyl. In another embodiment, R 5 HA-OC(O)R e In a further embodiment, R 5 HA-OC(O)OR hIn another embodiment, R 5 is -F. In another embodiment, R 5 -NHC(O)R e In a further embodiment, R 5 -NHS(=O)R e In another embodiment, R 5 -NHS(=O)2R e In a further embodiment, R 5 is -NHC(=S)NH(R h In another embodiment, R 5 is -NHC(O)NH(OH).

[0359] In one embodiment, R 3 is halogen, optionally substituted -C1-C6 alkyl, -CF3, cyano, -C(O)NR f R g , optionally replaced by (CR a 2) n Aryl, -SO2NR f R g , and -SO2R e In another embodiment, R 3 In a further embodiment, R 3 is alkyl of 1 to 4 carbons or cycloalkyl of 3 to 7 carbons. 3 is selected from the group consisting of halogen, optionally substituted -C1-C6 alkyl, optionally substituted -CH2 aryl, optionally substituted -CH(OH)aryl, -C(O)-amido, -S(=O)2-amido (wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methylpiperidinyl, morpholinyl, cyclohexylamino, anilinyl, and indolinyl), and -SOR a (where R e is selected from the group consisting of phenyl, 4-chlorophenyl, 4-fluorophenyl, and 4-pyridyl. 3 In yet another embodiment, R 3is selected from the group consisting of iodo, bromo, optionally substituted -C1-C6 alkyl, optionally substituted -CH2 aryl, optionally substituted -CH(OH)aryl, -(O)-amido, -S(=O)2-amido (wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclohexylamino, anilinyl, and indolinyl), and -SO2R e (where R e is selected from the group consisting of phenyl, 4-chlorophenyl, 4-fluorophenyl, and 4-pyridyl. 3 is -CH(OH)(4-fluorophenyl).

[0360] In one embodiment, X is -P(O)YR 11 Y'R 11 It is.

[0361] In one embodiment, X is -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR 1 ][-OR 11 ], and -P(O)[-OCH(V)CH2CH2O-], where V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl. In another aspect, -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-OCH2CH2SC(O)Me]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z2C(O)OR y ][-OR 11 ], and -P(O)[-OCH(V)CH2CH2O-], where V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl. In another embodiment, X is selected from the group consisting of -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-Oalk-SC(O)R y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR][-OR 11 ], and -P(O)[-OCH(V)CH2CH2O-], where V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl. In one aspect, X is selected from the group consisting of -PO3H2, -P(O)[-OCH2OC(O)-t-butyl]2, -P(O)[-OCH2OC(O)Oi-propyl]2, -P(O)[-N(H)CH(CH3)C(O)OCH2CH3]2, -P(O)[-N(H)C(CH3)2C(O)OCH2CH3]2, -P(O)[-N(H)CH(CH3)C(O)OCH2CH3][3,4-methylenedioxyphenyl], -P(O)[-N(H)C(CH3)2C(O)OCH2CH3][3,4-methylenedioxyphenyl], -P(O)[-O-CH2CH2S-C(O)CH3]2, and -P(O)[-OCH(3-chlorophenyl)CH2CH2O-]. In further embodiments, X is -PO3H2, -P(O)[-OCH2OC(O)-t-butyl]2, -P(O)[-OCH2OC(O)Oi-propyl]2, -P(O)[-N(CH(CH3)C(O)OCH2CH3]2, -P(O)[-N(H)C(CH3)2C(O)OCH2CH3]2, -P(O)[-N(H)CH(CH3)C(O)OCH2CH3][3,4-methylenedioxy-phenyl], -P(O )[-N(H)C(CH3)2C(O)OCH2CH3][3,4-methylenedioxyphenyl], and -P(O)[-OCH(3-chlorophenyl)CH2CHO-]. In another embodiment, X is -PO3H2. In yet another embodiment, X is selected from the group consisting of -P(O)[-OCH2OC(O)-t-butyl]2 and -P(O)[-OCH2OC(O)-i-propyl]2.

[0362] In one embodiment, X is selected from the group consisting of -P(O)[-OCH2OC(O)O-ethyl]2 and -P(O)[-OCH2OC(O)Oi-propyl]2. In another embodiment, X is selected from the group consisting of -P(O)[-N(F)CH(CH3)C(O)OCH2CH3]2 and -P(O)[-N(H)C(CH3)2C(O)OCH2CH3]2. In a further embodiment, X is -P(O)[-OCH2CH2SC(O)Me]2. In another embodiment, X is selected from the group consisting of -P(O)[-N(H)CH(CH3)C(O)OCH2CH3][3,4-methylenedioxyphenyl] and -P(O)[-N(H)C(CH3)2C(O)OCH2CH3][3,4-methylenedioxyphenyl]. In a further embodiment, X is -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ][-OR 11], and -P(O)[-OCH(V)CH2CH2O-], where V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl. In another embodiment, X is selected from the group consisting of -POH, -P(O)[-OCHOC(O)-t-butyl], -P(O)[-OCHOC(O)Oi-propyl], -P(O)[-N(H)CH(CH)C(O)OCHCH], -P(O)[-N(H)C(CH)C(O)OCHCH], -P(O)[-N(H)CH(CH)C(O)OCHCH][3,4-methylenedioxyphenyl], -P(O)[-N(H)C(CH)C(O)OCHCH][3,4-methylenedioxyphenyl], and -P(O)[-OCH(3-chlorophenyl)CHCHO-].

[0363] In another embodiment, X is -P(O)YR 11 Y'R 11 and

[0364] wherein Y and Y' are each independently selected from -O- and -NR-; R 11 and R 11 Together with the base:

[0365] [ka]

[0366] where:

[0367] V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl;

[0368] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, where 0-1 atom is a heteroatom and the remaining atoms are carbon and are substituted by hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy bonded to carbon atoms that are 3 atoms from both Y groups bonded to phosphorus;

[0369] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, fused to aryl groups at beta and gamma positions relative to Y bonded to phosphorus;

[0370] or V and W together form a cyclic group containing 6 optionally substituted carbon atoms bonded through an additional 3 carbon atoms and substituted by one substituent selected from the group consisting of hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy bonded to one of said carbon atoms which is 3 atoms from Y bonded to phosphorus;

[0371] or Z and W together are joined through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0372] or W and W' together are joined through an additional 2-5 atoms to form a cyclic group, where 0-2 atoms are heteroatoms and the remaining atoms are carbon, and V is aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0373] Z is -CHR z OH, -CHR z O.C.(O)R y , -CHR z OC(S)R y, -CHR z OC(S)OR y , -CHR 2 OC(O)SR y , -CHR z OCO2R y , -OR z , -SR z , -CHR e N3, -CH2aryl, -CH(aryl)OH, -CH(CH=CR z 2) OH, -CH(C≡CR z )OH, -R z , -NR z 2. -OCOR y , -OCO2R y , -SCOR y , -SCO2R y , -NHCOR e , -NHCO2R y , -CH2NHaryl, -(CH2)q-OR z , and -(CH2)q-SR z selected from the group consisting of;

[0374] q is an integer 2 or 3;

[0375] However, under the following conditions:

[0376] a) V, Z, W, W' are not all -H; and

[0377] b) Z is -R z when at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;

[0378] Each R z is R y and -H;

[0379] Each R y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

[0380] Each R vis selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl.

[0381] In one aspect, V is optionally substituted aryl. In another aspect, V is selected from the group consisting of 3-chlorophenyl, 4-chlorophenyl, 3-bromophenyl, 3-fluorophenyl, pyrid-4-yl, pyrid-3-yl, and 3,5-dichlorophenyl.

[0382] In one embodiment, the relative stereochemistry between the V-group substituent on the dioxaphosphonane ring and T is cis. In another embodiment, the cis dioxaphosphonane ring has R stereochemistry at the carbon to which V is attached. In another embodiment, the cis dioxaphosphonane ring has S stereochemistry at the carbon to which V is attached.

[0383] In one embodiment, R 11 is not hydrogen.

[0384] In a further embodiment, G is -O-, T is -CH-, and R 1 and R 2 are bromo, and R 3 is isopropyl, R 5 When is -OH, R 4 is not hydrogen. In another embodiment, G is -O- and T is -(CH2) 0~4 and R 1 and R 2 is independently selected from the group consisting of halogen, alkyl of 1 to 3 carbons, and cycloalkyl of 3 to 5 carbons; R 3 is an alkyl of 1 to 4 carbons or a cycloalkyl of 3 to 7 carbons, and R 5 When is -OH, R 4 is not hydrogen; where G is -O- and R 5 but,

[0385] NHC(O)R e , -NHS(=O) 1~2 R e , -NHC(=S)NH(R h), and -NHC(O)NH(R h ), T is selected from the group consisting of -(CH2) m -, -CH=CH-, -O(CH2) 1~2 - and -NH(CH2) 1~2 -, R 4 is not hydrogen. In a further embodiment of the compound of formula I, G is selected from the group consisting of -O- and -CH2-; T is -(CR a 2) n , -O(CR b 2)(CR a 2) p -, -N(R c )(CR b 2)(CR a 2) p -, -S(CR b 2)(CR a 2) p -, -NR b (CO)- and -CHCH(NR c R b )-; R 1 and R 2 are each independently selected from the group consisting of halogen, -C1-C4 alkyl, -CF3, and cyano; R 4 is selected from the group consisting of hydrogen, halogen, -C1-C4 alkyl, cyano, and CF3; R 5 -OH, -OC(O)R e , -OC(O)OR h , -F, and -NHC(O)R e R 3 is halogen, optionally substituted -C1-C6 alkyl, -CF3, cyano, -C(O)NR f R g , optionally replaced by -(CR a 2) n Aryl, -SO2NR f R g , and -SO2R e X is selected from the group consisting of -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)ORy ]2, -P(O)[-Oalk-SC(O)R y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ][-OR 11 ], and -P(O)[-OCH(V)CH2CH2O-], where V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl.

[0386] In another embodiment, G is selected from the group consisting of -O- and -CH2-; T is -(CR a 2) n , -O(CR b 2)(CR a 2) p -, -N(R c )2)(CR bb 2)(CR a 2) p -, -S(CR b 2)(CR a 2) p -, -NR b (CO)- and -CHCH(NR c R b )-; R 1 and R 2 are each independently selected from the group consisting of halogen, -C1-C4 alkyl, -CF3, and cyano; R 4 is selected from the group consisting of hydrogen, halogen, -C1-C4 alkyl, cyano, and CF3; R 1 -OH, -OC(O)R e , -OC(O)OR h , -F, and -NHC(O)R e R 3 is halogen, optionally substituted -C1-C6 alkyl, -CF3, cyano, -C(O)NR f R g , optionally replaced by -(CR a 2) n Aryl, -SO2NRf R g , and -SO2R e X is selected from the group consisting of -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-N(H) c R z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ][-OR 11 ], and -P(O)[-OCH(V)CH2CH2O-], where V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl.

[0387] In a further embodiment, G is selected from the group consisting of -O- and -CH2-; T is -CH2CH(NH2)-; and R 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano; R 4 is hydrogen; R 5 is -OH and -OC(O)R e R 3is selected from the group consisting of halogen, optionally substituted -C1-C6 alkyl, optionally substituted -CH2 aryl, optionally substituted -CH(OH)aryl, -C(O)-amido (wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclohexylamino, anilinyl, and indolinyl), -S(=O)2-amido (wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclohexylamino, anilinyl, and indolinyl), and -SOR (wherein R is selected from the group consisting of phenyl, 4-chlorophenyl, 4-fluorophenyl, and 4-pyridyl); and X is selected from the group consisting of -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ][OR e ], and -P(O)[-OCR z (aryl)CH2CH2O-].

[0388] In another embodiment, G is -O-, T is -CH-, and R 1 and R 2 is bromo and R 3 is isopropyl, R 5 is -OH, X is -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR e 2C(O)OR y ][OR e], and -P(O)[-OCR z (aryl)CH2CH2O-], R 4 is not hydrogen.

[0389] In one embodiment of the compound of formula I, G is -O-; T is -CHCH(NH)-; R 1 and R 2 are iodine; R 4 is selected from the group consisting of hydrogen and iodine; R 5 is -OH; R 3 is iodine; X is -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ][OR e ], and -P(O)[-OCR z (aryl)CH2CH2O-].

[0390] In another embodiment, G is -O-; T is -CHCH(NH)-; R 1 and R 2 are iodine; R 4 is selected from the group consisting of hydrogen and iodine; R 5 is -OH; R 3is iodo; and X is selected from the group consisting of -POH, -P(O)[-OCHOC(O)-t-butyl], -P(O)[-OCHOC(O)Oi-propyl], -P(O)[-N(H)CH(CH)C(O)OCHCH], -P(O)[-N(H)C(CH)C(O)OCHCH], -P(O)[-N(H)CH(CH)C(O)OCHCH][3,4-methylenedioxyphenyl], -P(O)[-N(H)C(CH)C(O)OCHCH][3,4-methylenedioxyphenyl], and -P(O)[-OCH(3-chlorophenyl)CHCHO-].

[0391] In a further embodiment of the compound of formula I, G is selected from the group consisting of -O- and -CH2-; T is -N(H)C(O)-; R 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano; R 4 is selected from the group consisting of hydrogen, iodo, 4-chlorophenyl, and cyclohexyl; R 5 is -OH and -OC(O)R e R 3 is selected from the group consisting of hydrogen, iodo, bromo, optionally substituted -C1-C6 alkyl, optionally substituted -CH2 aryl, optionally substituted -CH(OH)aryl, -C(O)-amido (wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclohexylamino, anilinyl, and indolinyl), -S(=O)2-amido (wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclohexylamino, anilinyl, and indolinyl), and -SOR (wherein R is selected from the group consisting of phenyl, 4-chlorophenyl, 4-fluorophenyl, and 4-pyridyl); X is selected from the group consisting of -PO3H2, -P(O)[-OCR z 2OC(O)R y]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ][OR e ], and -P(O)[-OCR z (aryl)CH2CH2O-].

[0392] In a further embodiment, G is -O-; T is -N(H)C(O)-; and R 1 and R 2 is methyl; R 4 is hydrogen and R 5 is -OH; R 3 is -CH(OH)(4-fluorophenyl); X is -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ][OR e ], and -P(O)[-OCR z (aryl)CH2CH2O-].

[0393] In a further embodiment, G is -O-; T is -N(H)C(O)-; R 1 and R 2 are each methyl; R 4 is hydrogen; R 5 is -OH; R 3is -CH(OH)(4-fluorophenyl); X is selected from the group consisting of -POH, -P(O)[-OCHOC(O)-t-butyl], -P(O)[-OCHOC(O)Oi-propyl], -P(O)[-N(H)CH(CH)C(O)OCHCH], -P(O)[-N(H)C(CH)C(O)OCHCH], -P(O)[-N(H)CH(CH)C(O)OCHCH][3,4-methylenedioxyphenyl], -P(O)[-N(H)C(CH)C(O)OCHCH][3,4-methylenedioxyphenyl], and -P(O)[-OCH(3-chlorophenyl)CHCHO-].

[0394] In a further embodiment, G is selected from the group consisting of -O- and -CH2-; T is -OCH2-; and R 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano; R 4 is selected from the group consisting of hydrogen, iodo, 4-chlorophenyl, and cyclohexyl; R 5 is -OH and -OC(O)R e R 3 is selected from the group consisting of hydrogen, iodo, bromo, optionally substituted lower alkyl, optionally substituted -CHaryl, optionally substituted -CH(OH)aryl, -C(O)-amido (wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclohexylamino, anilinyl, and indolinyl), -S(=O)2-amido (wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclohexylamino, anilinyl, and indolinyl), and -SOR (wherein R is selected from the group consisting of phenyl, 4-chlorophenyl, 4-fluorophenyl, and 4-pyridyl); X is selected from the group consisting of -PO3H2, -P(O)[-OCR z 2OC(O)R y]2, -P(O)[-OCR z 2OC(O)OR y ]2, P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ][OR e ], and -P(O)[-OCR z (aryl)CH2CH2O-].

[0395] In another embodiment, G is -CH2-; T is -OCH2-; and R 1 and R 2 are each methyl; R 4 is hydrogen; R 5 is -OH; R 3 is isopropyl; X is -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR a 2OC(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ][OR e ], and -P(O)[-OCR z (aryl)CH2CH2O-].

[0396] In another embodiment, G is -CH2-; T is -OCH2-; and R 1 and R 2 are each methyl; R 4 is hydrogen; R 5 is -OH; R 3is isopropyl; and X is selected from the group consisting of -POH, -P(O)[-OCHOC(O)-t-butyl], -P(O)[-OCHOC(O)Oi-propyl], -P(O)[-N(H)CH(CH)C(O)OCHCH], -P(O)[-N(H)C(CH)C(O)OCHCH], -P(O)[-N(H)CH(CH)C(O)OCHCH][3,4-methylenedioxyphenyl], -P(O)[-N(H)C(CH)C(O)OCHCH][3,4-methylenedioxyphenyl], and -P(O)[-OCH(3-chlorophenyl)CHCHO-].

[0397] In a further embodiment, G is selected from the group consisting of -O- and -CH2-; T is -CH2-; and R 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano; R 4 is selected from the group consisting of hydrogen, iodo, 4-chlorophenyl, and cyclohexyl; R 5 is -OH and -OC(O)R e R 3 is selected from the group consisting of hydrogen, iodo, bromo, optionally substituted lower alkyl, optionally substituted -CHaryl, optionally substituted -CH(OH)aryl, -C(O)-amido (wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclohexylamino, anilinyl, and indolinyl), -S(=O)2-amido (wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclohexylamino, anilinyl, and indolinyl), and -SOR (wherein R is selected from the group consisting of phenyl, 4-chlorophenyl, 4-fluorophenyl, and 4-pyridyl); X is selected from the group consisting of -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCRz 2OC(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ][OR e ], and -P(O)[-OCR z (aryl)CH2CH2O-].

[0398] In a further embodiment, G is -O-, T is -CH-, and R 1 and R 2 are bromo, and R 3 is isopropyl, R 5 is -OH; X is -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ][OR e ], and -P(O)[-OCR z (aryl)CH2CH2O-], R 4 is not hydrogen.

[0399] In another embodiment, G is -O-; T is -CH-; and R 1 and R 2 are each chloro; R 4 is hydrogen; R 5 -OH; R 3 is i-propyl; X is -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z2C(O)OR y ][OR e ], and -P(O)[-OCR z (aryl)CH2CH2O-].

[0400] In another embodiment, G is -O-; T is -CH-; R and R 2 are each chloro; R 4 is hydrogen; R 5 is -OH; R 3 is i-propyl; and X is selected from the group consisting of -POH, -P(O)[-OCHOC(O)-t-butyl], -P(O)[-OCHOC(O)Oi-propyl], -P(O)[-N(H)CH(CH)C(O)OCHCH], -P(O)[-N(H)C(CH)C(O)OCHCH], -P(O)[-N(H)CH(CH)C(O)OCHCH][3,4-methylenedioxyphenyl], -P(O)[-N(H)C(CH)C(O)OCHCH][3,4-methylenedioxyphenyl], and -P(O)[-OCH(3-chlorophenyl)CHCHO-].

[0401] In a further embodiment of the compound of formula I, G is selected from the group consisting of -O- and -CH2-; T is -CH2CH2-; and R 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano; R 4 is selected from the group consisting of hydrogen, iodo, 4-chlorophenyl, and cyclohexyl; R 5 is -OH and -OC(O)R e R 3is selected from the group consisting of hydrogen, iodo, bromo, optionally substituted lower alkyl, optionally substituted -CHaryl, optionally substituted -CH(OH)aryl, -C(O)-amido (wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclohexylamino, anilinyl, and indolinyl), -S(=O)2-amido (wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclohexylamino, anilinyl, and indolinyl), and -SOR (wherein R is selected from the group consisting of phenyl, 4-chlorophenyl, 4-fluorophenyl, and 4-pyridyl); X is selected from the group consisting of -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ][OR e ], and -P(O)[-OCR z (aryl)CH2CH2O-].

[0402] In a further embodiment, G is -O-; T is -CHCH-; and R 1 and R 2 are each chloro; R 4 is hydrogen, and R 5 is -OH; R 3 is isopropyl; X is -PO3H2, -P(O)[-OCR z 2OC(O)R y ]2, -P(O)[-OCR z 2OC(O)OR y ]2, -P(O)[-N(H)CR z 2C(O)OR y ]2, -P(O)[-N(H)CR z2C(O)OR y ][OR e ], and -P(O)[-OCR z (aryl)CH2CH2O-].

[0403] In another embodiment, G is -O-; T is -CHCH-; and R 1 and R 2 are each chloro; R 4 is hydrogen; R 5 is -OH; R 3 is isopropyl; and X is selected from the group consisting of -POH, -P(O)[-OCHOC(O)-t-butyl], -P(O)[-OCHOC(O)Oi-propyl], -P(O)[-N(H)CH(CH)C(O)OCHCH], -P(O)[-N(H)C(CH)C(O)OCHCH], -P(O)[-N(H)CH(CH)C(O)OCHCH][3,4-methylenedioxyphenyl], -P(O)[-N(H)C(CH)C(O)OCHCH][3,4-methylenedioxyphenyl], and -P(O)[-OCH(3-chlorophenyl)CHCHO-].

[0404] In a further embodiment, G is -CH2-; T is -OCH2-; and R 1 and R 2 are each methyl; R 4 is hydrogen; R 5 is -OH; R 3 is isopropyl; X is -PO3H2. In a further embodiment, G is -CH2-; T is -OCH2-; R 1 and R 2 are each methyl; R 4 is hydrogen; R 5 is -OH; R 3 is isopropyl; X is selected from the group consisting of -P(O)[-OCH2OC(O)-t-butyl]2 and -P(O)[-OCH2OC(O)-i-propyl]2. In another embodiment, G is -CH2-; T is -OCH2-; R 1 and R 2are each methyl; R 4 is hydrogen; R 5 is -OH; R 3 is isopropyl; X is selected from the group consisting of -P(O)[-OCH2OC(O)O-ethyl]2 and -P(O)[-OCH2OC(O)-i-propyl]2. In further embodiments, G is -CH2-; T is -OCH2-; R 1 and R 2 are each methyl; R 4 is hydrogen; R 5 is -OH; R 3 is isopropyl; X is selected from the group consisting of -P(O)[-N(H)CH(CH3)C(O)OCH2CH3]2 and -P(O)[-N(H)C(CH3)2C(O)OCH2CH3]2. In further embodiments, G is -CH2-; T is -OCH2-; R 1 and R 2 is methyl; R 4 is hydrogen; R 5 is -OH; R 3 is isopropyl; X is -P(O)[-OCHCHSC(O)Me], or X is -P(O)[-N(H)C(CH)C(O)OCHCH][3,4-methylenedioxyphenyl], or X is -P(O)[-N(H)C(CH)C(O)OCHCH][3,4-methylenedioxyphenyl].

[0405] In another embodiment, G is -O- and T is -(CH) 0~4 - and R 1 and R 2 is independently selected from the group consisting of hydrogen, halogen, alkyl of 1 to 3 carbons, and cycloalkyl of 3 to 5 carbons; R 3 is an alkyl of 1 to 4 carbons or a cycloalkyl of 3 to 7 carbons; R 5 is -OH, then R 4 is not hydrogen; where G is -O- and R 5 However, NHC(O)R e , -NHS(=O) 1~2 R e, -NHC(S)NH(Th), and -NHC(O)NH(R h ), T is selected from the group consisting of -(CH2) m -, -CH=CH-, -O(CH2) 1~2 - and -NH(CH2) 1~2 -, R 4 is not hydrogen.

[0406] In a further embodiment, G is -CH2-; T is -OCH2-; and R 1 and R 2 are each methyl; R 1 is hydrogen; R 5 is -OH; R 3 is isopropyl; X is -P(O)YR 11 Y'R 11 It is.

[0407] In the formula, Y and Y′ are each independently —O— or —NR v - selected from;R 11 and R 11 Together with the base:

[0408] [ka]

[0409] where:

[0410] V, W, and W' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl;

[0411] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, where 0-1 atom is a heteroatom and the remaining atoms are carbon and are substituted by hydroxy, acyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy bonded to carbon atoms that are 3 atoms from both Y groups bonded to phosphorus;

[0412] or V and Z together are linked through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, fused to aryl groups at beta and gamma positions relative to Y bonded to phosphorus;

[0413] or V and W together form a cyclic group containing 6 optionally substituted carbon atoms bonded through an additional 3 carbon atoms and substituted by one substituent selected from the group consisting of hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy bonded to one of said carbon atoms which is 3 atoms from Y bonded to phosphorus;

[0414] or Z and W together are joined through an additional 3-5 atoms to form a cyclic group, where 0-1 atoms are heteroatoms and the remaining atoms are carbon, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0415] or W and W' together are joined through an additional 2-5 atoms to form a cyclic group, where 0-2 atoms are heteroatoms and the remaining atoms are carbon, and V is aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

[0416] Z is -CHR z OH, -CHR z O.C.(O)R y , -CHR z OC(S)R y , -CHR zOC(S)OR y , -CHR z OC(O)SR y , -CHR z OCO2R y , -OR z , -SR z , -CHR z N3, -CH2aryl, -CH(aryl)OH, -CH(CH=CR z 2) OH, -CH(C≡CR z )OH, -R z , -NR z 2. -OCOR y , -OCO2R y , -SCOR y , -SCO2R y , -NHCOR z , -NHCO2R y , -CH2NHaryl, -(CH2)q-OR z , and -(CH2)q-SR z selected from the group consisting of;

[0417] q is an integer 2 or 3;

[0418] However, under the following conditions:

[0419] a) V, Z, W, W' are not all -H; and

[0420] b) Z is -R z when at least one of V, W, and W' is not -H, alkyl, aralkyl, or heterocycloalkyl;

[0421] Each R z is R y and -H;

[0422] Each R y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;

[0423] Each R x is independently selected from the group consisting of -H and alkyl, or Rx and R x together form a cyclic alkyl group;

[0424] Each R v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl. In a further embodiment, V is aryl. In a further embodiment, Z is hydrogen, W is hydrogen, and W' is hydrogen. In a further embodiment, V is 3-chlorophenyl, 4-chlorophenyl, 3-bromophenyl, 3-fluorophenyl, pyrid-4-yl, pyrid-3-yl, or 3,5-dichlorophenyl. In a further embodiment, the relative stereochemistry between the substituents on the dioxaphosphonane ring is cis.

[0425] In another embodiment, each R a are independently hydrogen, optionally substituted -C1-C2 alkyl, halogen, -OH, optionally substituted -O-C1-C2 alkyl, -OCF3, optionally substituted -S-C1-C2 alkyl, -NR b R c , optionally substituted -C2 alkenyl, and optionally substituted -C2 alkynyl;

[0426] Each R b is independently selected from the group consisting of hydrogen, optionally substituted -C1-C2 alkyl;

[0427] Each R c is independently selected from the group consisting of hydrogen, and optionally substituted -C1-C4 alkyl, optionally substituted -C(O)-C1-C2 alkyl, -C(O)H;

[0428] Each R d is an optionally substituted -C1-C6 alkyl, an optionally substituted -C2-C6 alkenyl, an optionally substituted -C2-C6 alkynyl, an optionally substituted -(CR b 2) n Phenyl, optionally substituted -(CR b2) n Acyclic Heteroaryl, optionally substituted -(CR b 2) n -C3-C6-cycloalkyl, optionally substituted -(CR b 2) n -C4-C5-heterocycloalkyl, and -C(O)NR f R g selected from the group consisting of;

[0429] Each R e is an optionally substituted -C1-C6 alkyl, an optionally substituted -C2-C6 alkenyl, an optionally substituted -C2-C6 alkynyl, an optionally substituted -(CR b 2) n Phenyl, optionally substituted -(CR b 2) n Monocyclic heteroaryl, optionally substituted -(CR b 2) n -C3-C6-cycloalkyl, optionally substituted -(CR b 2) n -C4-C5-heterocycloalkyl;

[0430] R f and R g are each independently hydrogen, an optionally substituted -C1-C6 alkyl, an optionally substituted -C2-C6 alkenyl, an optionally substituted -C2-C6 alkynyl, an optionally substituted -(CR b 2) n Phenyl, optionally substituted -(CR b 2) n Monocyclic heteroaryl, optionally substituted -(CR b 2) n -C3-C6-cycloalkyl, optionally substituted -(CR b 2) n -C4-C5-heterocycloalkyl or R f and R g Together, O, NR band S, wherein the optionally substituted heterocycle is an optionally substituted -C1-C2 alkyl, -OR b , oxo, cyano, -CF3, optionally substituted phenyl, and -C(O)OR h may be substituted with 0 to 2 substituents selected from the group consisting of:

[0431] Each R h is optionally substituted -C1~C 16 Alkyl, optionally substituted -C to C 16 Alkenyl, optionally substituted -C 16 Alkynyl, optionally substituted -(CR b 2) n Phenyl, optionally substituted -(CR b 2) n Monocyclic heteroaryl, optionally substituted -(CR b 2) n -C3-C6-cycloalkyl, optionally substituted -CR b 2) n -C4-C5-heterocycloalkyl.

[0432] In a further embodiment, each R a is independently selected from the group consisting of hydrogen, methyl, fluoro, chloro, -OH, -O-CH3, -OCF3, -SCH3, -NHCH3, -N(CH3)2;

[0433] Each R b is independently selected from the group consisting of hydrogen and methyl;

[0434] Each R c is independently selected from the group consisting of hydrogen, methyl, -C(O)CH3, -C(O)H;

[0435] Each R dis an optionally substituted -C1-C4 alkyl, an optionally substituted -C2-C4 alkenyl, an optionally substituted -C2-C4 alkynyl, an optionally substituted -(CH2) n Phenyl, optionally substituted -(CH2) n Monocyclic Heteroaryl, Optionally Substituted -(CH2) n -C3-C6-cycloalkyl, optionally substituted -(CH2) n -C4-C5-heterocycloalkyl, and -C(O)NR f R g selected from the group consisting of;

[0436] Each R e is an optionally substituted -C1-C4 alkyl, an optionally substituted -C2-C4 alkenyl, an optionally substituted -C2-C4 alkynyl, an optionally substituted -(CH2) n Phenyl, optionally substituted -(CH2) n Monocyclic Heteroaryl, Optionally Substituted -(CH2) n -C3-C6-cycloalkyl, optionally substituted -(CH2) n , -C4-C5-heterocycloalkyl;

[0437] R f and R g are each independently hydrogen, an optionally substituted -C1-C4 alkyl, an optionally substituted -C2-C4 alkenyl, an optionally substituted -C2-C4 alkynyl, an optionally substituted -(CH2) n phenyl, optionally substituted -CH n Monocyclic Heteroaryl, Optionally Substituted -(CH2) n -C3-C6-cycloalkyl, optionally substituted -(CH2) n -C4-C8-heterocycloalkyl or R f and R g Together, O, NR band S, wherein the optionally substituted heterocycle is an optionally substituted methyl, -OR b , oxo, cyano, -CF3, optionally substituted phenyl, and -C(O)OR h may be substituted with 0 to 2 substituents selected from the group consisting of:

[0438] Each R h is an optionally substituted -C1-C4 alkyl, an optionally substituted -C2-C4 alkenyl, an optionally substituted -C2-C4 alkynyl, an optionally substituted -(CH2) n phenyl, optionally substituted -CH n Monocyclic Heteroaryl, Optionally Substituted -(CH2) n -C3-C6-cycloalkyl, optionally substituted -(CH2)6-C4-C8-heterocycloalkyl.

[0439] Exemplary compounds for incorporation into compositions for administration in the methods of the present disclosure include, but are not limited to, those disclosed in U.S. Patent No. 7,829,552, the entire contents of which are incorporated herein by reference. U.S. Patent No. 7,829,552 further discloses methods for synthesizing said compounds. Such compounds include those having the following structure, or a pharma- ceutically acceptable salt thereof:

[0440] [Table 2A]

[0441] [Table 2B]

[0442] [Table 2C]

[0443]

Table 2D

[0444]

Table 2E

[0445]

Table 2F

[0446]

Table 2G

[0447]

Table 2H

[0448]

Table 2I

[0449]

Table 2J

[0450]

Table 2K

[0451]

Table 2L

[0452]

Table 2M

[0453]

Table 2N

[0454]

Table 2O

[0455]

Table 2P

[0456]

Table 2Q

[0457]

Table 2R

[0458]

Table 2S

[0459]

Table 2T

[0460]

Table 2U

[0461]

Table 2V

[0462]

Table 2W

[0463]

Table 2X

[0464] [Table 2Y]

[0465] [Table 2Z]

[0466] Preferred compositions for administration according to the methods of the disclosure include compounds 1, 2, 3, and / or 4, which correspond to the following structures:

[0467] [ka]

[0468] or a pharma- ceutically acceptable salt thereof.

[0469] In some embodiments, the compound administered by the compositions and methods of the present disclosure is one of the following:

[0470] [Table 3A]

[0471] [Table 3B]

[0472] [Table 3C]

[0473] [Table 3D]

[0474] [Table 3E]

[0475] or a pharma- ceutically acceptable salt thereof, or any combination thereof.

[0476] In some other embodiments, the compound administered according to the compositions and methods of the present disclosure is

[0477] [Table 4A]

[0478] [Table 4B]

[0479] [Table 4C]

[0480] [Table 4D]

[0481] or a pharma- ceutically acceptable salt thereof, or any combination thereof.

[0482] In previous clinical trials, daily administration of these compounds to dogs resulted in a dose-dependent reduction in serum lipid levels and suppression of the HPT axis with unknown dose-dependence. Surprisingly, given the dose-dependence of the initial lipid-lowering effect, changing the administration schedule to every other day did not result in a decrease in efficacy in terms of lowering plasma cholesterol, but did reduce the suppression of the HPT axis. Thus, some embodiments include methods of administering Compound 1, Compound 2, and related compounds in such a way as to preserve their primary effect as agonists of TRβ and the reduction of clinical symptoms achieved thereby, while improving or eliminating the suppression of the HPT axis and the side effects associated with such suppression.

[0483] According to the methods disclosed herein, reduction of HPT suppression side effects associated with administration of the above-mentioned compounds may be achieved by adjusting the administration schedule so that the subject experiences periodic partial or complete reductions in administration followed by resumption of administration over a period of time. In some embodiments, a dose is administered daily for 1-30 days, followed by a rest period of 1-30 days. In some embodiments, no doses are administered during the rest period. In some further embodiments, the compound and its metabolites are allowed to be completely cleared from the subject's body before the next dose is administered. In some other embodiments, less than the normal daily dose is administered during the rest period. In some further embodiments, a less than therapeutically effective amount of the administered compound is maintained in the subject during the rest period. In some further embodiments, a sufficient amount of the administered compound is maintained in the subject to maintain therapeutic levels in the affected tissue.

[0484] In some embodiments, the maximum serum concentration of the compound during the dosing schedule is less than 120 ng / ml, less than 100 ng / ml, less than 90 ng / ml, less than 80 ng / ml, less than 70 ng / ml, less than 60 ng / ml, or less than 50 ng / ml. In some embodiments, the minimum serum concentration during the dosing schedule is less than 10 ng / ml, less than 1 ng / ml, less than 0.1 ng / ml, less than 0.01 ng / ml, or less than 0.001 ng / ml. In some embodiments, the level of the compound administered during the dosing schedule may be undetectable during some portions of the drug holiday.

[0485] In some embodiments, the maximum serum concentration of the compound during the dosing schedule is high during the initial ramp-up phase of dosing and low thereafter. In some embodiments, the maximum serum concentration of the compound during the initial (loading) phase of dosing is less than 500ng / ml, less than 400ng / ml, less than 300ng / ml, less than 200ng / ml, less than 150ng / ml, less than 120ng / ml, less than 100ng / ml, less than 90ng / ml, less than 80ng / ml, less than 70ng / ml, less than 60ng / ml, or less than 50ng / ml. In some such embodiments, the maximum serum concentration during the initial phase of dosing is between 5ng / ml and 250ng / ml. In some embodiments, the maximum serum concentration of the compound during the subsequent (maintenance) phase of administration is less than 350 ng / ml, less than 200 ng / ml, less than 120 ng / ml, less than 100 ng / ml, less than 90 ng / ml, less than 80 ng / ml, less than 70 ng / ml, less than 60 ng / ml, or less than 50 ng / ml, less than 40 ng / ml, less than 35 ng / ml, or less than 10 ng / ml. Those skilled in the art will readily recognize such methods for monitoring the serum concentration of pharmaceutical agents as exist in the art, and means for adjusting the dosage of the compounds disclosed herein to achieve the desired serum concentration. In some embodiments, the weekly dose administered is 600 mg or less. In some embodiments, the weekly dose administered is 500 mg or less, 400 mg or less, 300 mg or less, 200 mg or less, 100 mg or less, 50 mg or less, 40 mg or less, 25 mg or less, 10 mg or less, 5 mg or less, or within a range defined by any two of the foregoing.

[0486] In some embodiments, a compound of formula I in which each R is not hydrogen is administered, and the compound is metabolized in vivo to form a compound of formula I in which each R is hydrogen, or an anion of such a compound. For example, in some embodiments, compound 1 is administered, which is metabolized in vivo to form compound 3. In some embodiments, compound 2 is administered, which is metabolized in vivo to form compound 4. In some such embodiments, the maximum serum concentration of a compound of formula I in which each R is hydrogen, or an anion of such a compound (e.g., compound 3 or 4) during the initial (loading) phase of administration is 500 ng / ml or less, 450 ng / ml or less, 400 ng / ml or less, 350 ng / ml or less, 300 ng / ml or less, or 250 ng / ml or less. In some embodiments, the maximum serum concentration during the subsequent (maintenance) dosing phase is 500 ng / ml or less, 450 ng / ml or less, 400 ng / ml or less, 350 ng / ml or less, 300 ng / ml, 250 ng / ml or less, 200 ng / ml or less, 150 ng / ml or less, or 120 ng / ml or less.

[0487] According to the present disclosure, the dosing schedule may be varied to achieve the desired therapeutic effect while eliminating HPT-related side effects. In each of the following embodiments, the variations in the dosing schedule as described may be repeated throughout the treatment period. In each of the following embodiments, the first dose may be greater than, less than, or the same as the dose following the first dose. In each of the following embodiments, a loading dose may precede the disclosed dosing regimen, and a rest period may or may not follow the administration of the loading dose.

[0488] In some embodiments, the dose is administered every other day during the treatment period. In other embodiments, the dose is administered twice every three days during the treatment period. In yet other embodiments, the dose is administered twice every four days during the treatment period. In some embodiments, the dose is administered daily for one day, followed by a two-day rest period. In some embodiments, the dose is administered daily for one day, followed by a two-day rest period. In some embodiments, the dose is administered daily for one day, followed by a three-day rest period. In some embodiments, the dose is administered daily for one day, followed by a four-day rest period. In some embodiments, the dose is administered daily for one day, followed by a five-day rest period. In some embodiments, the dose is administered daily for one day, followed by a six-day rest period. In some embodiments, the dose is administered daily for one day, followed by a seven-day rest period. In some embodiments, the dose is administered daily for one day, followed by an eight-day rest period. In some embodiments, a dose is administered daily for one day, followed by a nine day rest period. In some embodiments, a dose is administered daily for one day, followed by a ten day rest period. In some embodiments, a dose is administered daily for one day, followed by an eleven day rest period. In some embodiments, a dose is administered daily for one day, followed by a twelve day rest period. In some embodiments, a dose is administered daily for one day, followed by a thirteen day rest period. In some embodiments, a dose is administered daily for one day, followed by a fourteen day rest period.

[0489] In some embodiments, a dose is administered daily for two days, followed by a one day rest period. In some embodiments, a dose is administered daily for two days, followed by a two day rest period. In some embodiments, a dose is administered daily for two days, followed by a three day rest period. In some embodiments, a dose is administered daily for two days, followed by a four day rest period. In some embodiments, a dose is administered daily for two days, followed by a five day rest period. In some embodiments, a dose is administered daily for two days, followed by a six day rest period. In some embodiments, a dose is administered daily for two days, followed by a seven day rest period. In some embodiments, a dose is administered daily for two days, followed by an eight day rest period. In some embodiments, a dose is administered daily for two days, followed by a nine day rest period. In some embodiments, a dose is administered daily for two days, followed by a ten day rest period. In some embodiments, a dose is administered daily for two days, followed by an eleven day rest period. In some embodiments, a dose is administered daily for two days, followed by a 12-day rest period. In some embodiments, a dose is administered daily for two days, followed by a 13-day rest period. In some embodiments, a dose is administered daily for two days, followed by a 14-day rest period.

[0490] In some embodiments, a dose is administered daily for three days, followed by a one day rest period. In some embodiments, a dose is administered daily for three days, followed by a two day rest period. In some embodiments, a dose is administered daily for three days, followed by a three day rest period. In some embodiments, a dose is administered daily for three days, followed by a four day rest period. In some embodiments, a dose is administered daily for three days, followed by a five day rest period. In some embodiments, a dose is administered daily for three days, followed by a six day rest period. In some embodiments, a dose is administered daily for three days, followed by a seven day rest period. In some embodiments, a dose is administered daily for three days, followed by an eight day rest period. In some embodiments, a dose is administered daily for three days, followed by a nine day rest period. In some embodiments, a dose is administered daily for three days, followed by a ten day rest period. In some embodiments, a dose is administered daily for three days, followed by an eleven day rest period. In some embodiments, a dose is administered daily for three days, followed by a 12-day rest period. In some embodiments, a dose is administered daily for three days, followed by a 13-day rest period. In some embodiments, a dose is administered daily for three days, followed by a 14-day rest period.

[0491] In some embodiments, a dose is administered daily for four days, followed by a one day rest period. In some embodiments, a dose is administered daily for four days, followed by a two day rest period. In some embodiments, a dose is administered daily for four days, followed by a three day rest period. In some embodiments, a dose is administered daily for four days, followed by a four day rest period. In some embodiments, a dose is administered daily for four days, followed by a five day rest period. In some embodiments, a dose is administered daily for four days, followed by a six day rest period. In some embodiments, a dose is administered daily for four days, followed by a seven day rest period. In some embodiments, a dose is administered daily for four days, followed by an eight day rest period. In some embodiments, a dose is administered daily for four days, followed by a nine day rest period. In some embodiments, a dose is administered daily for four days, followed by a ten day rest period. In some embodiments, a dose is administered daily for four days, followed by an eleven day rest period. In some embodiments, a dose is administered daily for 4 days followed by a 12-day rest period. In some embodiments, a dose is administered daily for 4 days followed by a 13-day rest period. In some embodiments, a dose is administered daily for 4 days followed by a 14-day rest period.

[0492] In some embodiments, a dose is administered daily for five days, followed by a one day rest period. In some embodiments, a dose is administered daily for five days, followed by a two day rest period. In some embodiments, a dose is administered daily for five days, followed by a three day rest period. In some embodiments, a dose is administered daily for five days, followed by a four day rest period. In some embodiments, a dose is administered daily for five days, followed by a five day rest period. In some embodiments, a dose is administered daily for five days, followed by a six day rest period. In some embodiments, a dose is administered daily for five days, followed by a seven day rest period. In some embodiments, a dose is administered daily for five days, followed by a eight day rest period. In some embodiments, a dose is administered daily for five days, followed by a nine day rest period. In some embodiments, a dose is administered daily for five days, followed by a ten day rest period. In some embodiments, a dose is administered daily for five days, followed by an eleven day rest period. In some embodiments, the dose is administered daily for 5 days followed by a 12 day rest period. In some embodiments, the dose is administered daily for 5 days followed by a 13 day rest period. In some embodiments, the dose is administered daily for 5 days followed by a 14 day rest period.

[0493] In some embodiments, a dose is administered daily for six days, followed by a one day rest period. In some embodiments, a dose is administered daily for six days, followed by a two day rest period. In some embodiments, a dose is administered daily for six days, followed by a three day rest period. In some embodiments, a dose is administered daily for six days, followed by a four day rest period. In some embodiments, a dose is administered daily for six days, followed by a five day rest period. In some embodiments, a dose is administered daily for six days, followed by a six day rest period. In some embodiments, a dose is administered daily for six days, followed by a seven day rest period. In some embodiments, a dose is administered daily for six days, followed by an eight day rest period. In some embodiments, a dose is administered daily for six days, followed by a nine day rest period. In some embodiments, a dose is administered daily for six days, followed by a ten day rest period. In some embodiments, a dose is administered daily for six days, followed by an eleven day rest period. In some embodiments, the dose is administered daily for 6 days followed by a 12 day rest period. In some embodiments, the dose is administered daily for 6 days followed by a 13 day rest period. In some embodiments, the dose is administered daily for 6 days followed by a 14 day rest period.

[0494] In some embodiments, a dose is administered daily for 7 days, followed by a 1 day rest period. In some embodiments, a dose is administered daily for 7 days, followed by a 2 day rest period. In some embodiments, a dose is administered daily for 7 days, followed by a 3 day rest period. In some embodiments, a dose is administered daily for 7 days, followed by a 4 day rest period. In some embodiments, a dose is administered daily for 7 days, followed by a 5 day rest period. In some embodiments, a dose is administered daily for 7 days, followed by a 6 day rest period. In some embodiments, a dose is administered daily for 7 days, followed by a 7 day rest period. In some embodiments, a dose is administered daily for 7 days, followed by a 8 day rest period. In some embodiments, a dose is administered daily for 7 days, followed by a 9 day rest period. In some embodiments, a dose is administered daily for 7 days, followed by a 10 day rest period. In some embodiments, a dose is administered daily for 7 days, followed by an 11 day rest period. In some embodiments, the dose is administered daily for 7 days followed by a 12 day rest period. In some embodiments, the dose is administered daily for 7 days followed by a 13 day rest period. In some embodiments, the dose is administered daily for 7 days followed by a 14 day rest period.

[0495] In some embodiments, a dose is administered daily for 8 days, followed by a 1 day rest period. In some embodiments, a dose is administered daily for 8 days, followed by a 2 day rest period. In some embodiments, a dose is administered daily for 8 days, followed by a 3 day rest period. In some embodiments, a dose is administered daily for 8 days, followed by a 4 day rest period. In some embodiments, a dose is administered daily for 8 days, followed by a 5 day rest period. In some embodiments, a dose is administered daily for 8 days, followed by a 6 day rest period. In some embodiments, a dose is administered daily for 8 days, followed by a 7 day rest period. In some embodiments, a dose is administered daily for 8 days, followed by an 8 day rest period. In some embodiments, a dose is administered daily for 8 days, followed by a 9 day rest period. In some embodiments, a dose is administered daily for 8 days, followed by a 10 day rest period. In some embodiments, a dose is administered daily for 8 days, followed by an 11 day rest period. In some embodiments, the dose is administered daily for 8 days followed by a 12 day rest period. In some embodiments, the dose is administered daily for 8 days followed by a 13 day rest period. In some embodiments, the dose is administered daily for 8 days followed by a 14 day rest period.

[0496] In some embodiments, a dose is administered daily for 9 days, followed by a 1 day rest period. In some embodiments, a dose is administered daily for 9 days, followed by a 2 day rest period. In some embodiments, a dose is administered daily for 9 days, followed by a 3 day rest period. In some embodiments, a dose is administered daily for 9 days, followed by a 4 day rest period. In some embodiments, a dose is administered daily for 9 days, followed by a 5 day rest period. In some embodiments, a dose is administered daily for 9 days, followed by a 6 day rest period. In some embodiments, a dose is administered daily for 9 days, followed by a 7 day rest period. In some embodiments, a dose is administered daily for 9 days, followed by an 8 day rest period. In some embodiments, a dose is administered daily for 9 days, followed by a 9 day rest period. In some embodiments, a dose is administered daily for 9 days, followed by a 10 day rest period. In some embodiments, a dose is administered daily for 9 days, followed by an 11 day rest period. In some embodiments, the dose is administered daily for 9 days followed by a 12 day rest period. In some embodiments, the dose is administered daily for 9 days followed by a 13 day rest period. In some embodiments, the dose is administered daily for 9 days followed by a 14 day rest period.

[0497] In some embodiments, the dose is administered daily for 10 days, followed by a 1-day rest period. In some embodiments, the dose is administered daily for 10 days, followed by a 2-day rest period. In some embodiments, the dose is administered daily for 10 days, followed by a 3-day rest period. In some embodiments, the dose is administered daily for 10 days, followed by a 4-day rest period. In some embodiments, the dose is administered daily for 10 days, followed by a 5-day rest period. In some embodiments, the dose is administered daily for 10 days, followed by a 6-day rest period. In some embodiments, the dose is administered daily for 10 days, followed by a 7-day rest period. In some embodiments, the dose is administered daily for 10 days, followed by an 8-day rest period. In some embodiments, the dose is administered daily for 10 days, followed by a 9-day rest period. In some embodiments, the dose is administered daily for 10 days, followed by a 10-day rest period. In some embodiments, the dose is administered daily for 10 days, followed by an 11-day rest period. In some embodiments, the dose is administered daily for 10 days, followed by a 12-day rest period. In some embodiments, the dose is administered daily for 10 days, followed by a 13-day rest period. In some embodiments, the dose is administered daily for 10 days, followed by a 14-day rest period.

[0498] In some embodiments, the dose is administered daily for 11 days, followed by a 1-day rest period. In some embodiments, the dose is administered daily for 11 days, followed by a 2-day rest period. In some embodiments, the dose is administered daily for 11 days, followed by a 3-day rest period. In some embodiments, the dose is administered daily for 11 days, followed by a 4-day rest period. In some embodiments, the dose is administered daily for 11 days, followed by a 5-day rest period. In some embodiments, the dose is administered daily for 11 days, followed by a 6-day rest period. In some embodiments, the dose is administered daily for 11 days, followed by a 7-day rest period. In some embodiments, the dose is administered daily for 11 days, followed by an 8-day rest period. In some embodiments, the dose is administered daily for 11 days, followed by a 9-day rest period. In some embodiments, the dose is administered daily for 11 days, followed by a 10-day rest period. In some embodiments, the dose is administered daily for 11 days, followed by an 11-day rest period. In some embodiments, the dose is administered daily for 11 days, followed by a 12-day rest period. In some embodiments, the dose is administered daily for 11 days, followed by a 13-day rest period. In some embodiments, the dose is administered daily for 11 days, followed by a 14-day rest period.

[0499] In some embodiments, the dose is administered daily for 12 days, followed by a 1-day rest period. In some embodiments, the dose is administered daily for 12 days, followed by a 2-day rest period. In some embodiments, the dose is administered daily for 12 days, followed by a 3-day rest period. In some embodiments, the dose is administered daily for 12 days, followed by a 4-day rest period. In some embodiments, the dose is administered daily for 12 days, followed by a 5-day rest period. In some embodiments, the dose is administered daily for 12 days, followed by a 6-day rest period. In some embodiments, the dose is administered daily for 12 days, followed by a 7-day rest period. In some embodiments, the dose is administered daily for 12 days, followed by an 8-day rest period. In some embodiments, the dose is administered daily for 12 days, followed by a 9-day rest period. In some embodiments, the dose is administered daily for 12 days, followed by a 10-day rest period. In some embodiments, the dose is administered daily for 12 days, followed by an 11-day rest period. In some embodiments, the dose is administered daily for 12 days, followed by a 12-day rest period. In some embodiments, the dose is administered daily for 12 days, followed by a 13-day rest period. In some embodiments, the dose is administered daily for 12 days, followed by a 14-day rest period.

[0500] In some embodiments, the dose is administered daily for 13 days, followed by a 1-day rest period. In some embodiments, the dose is administered daily for 13 days, followed by a 2-day rest period. In some embodiments, the dose is administered daily for 13 days, followed by a 3-day rest period. In some embodiments, the dose is administered daily for 13 days, followed by a 4-day rest period. In some embodiments, the dose is administered daily for 13 days, followed by a 5-day rest period. In some embodiments, the dose is administered daily for 13 days, followed by a 6-day rest period. In some embodiments, the dose is administered daily for 13 days, followed by a 7-day rest period. In some embodiments, the dose is administered daily for 13 days, followed by an 8-day rest period. In some embodiments, the dose is administered daily for 13 days, followed by a 9-day rest period. In some embodiments, the dose is administered daily for 13 days, followed by a 10-day rest period. In some embodiments, the dose is administered daily for 13 days, followed by an 11-day rest period. In some embodiments, the dose is administered daily for 13 days, followed by a 12-day rest period. In some embodiments, the dose is administered daily for 13 days, followed by a 13-day rest period. In some embodiments, the dose is administered daily for 13 days, followed by a 14-day rest period.

[0501] In some embodiments, the dose is administered daily for 14 days, followed by a 1-day rest period. In some embodiments, the dose is administered daily for 14 days, followed by a 2-day rest period. In some embodiments, the dose is administered daily for 14 days, followed by a 3-day rest period. In some embodiments, the dose is administered daily for 14 days, followed by a 4-day rest period. In some embodiments, the dose is administered daily for 14 days, followed by a 5-day rest period. In some embodiments, the dose is administered daily for 14 days, followed by a 6-day rest period. In some embodiments, the dose is administered daily for 14 days, followed by a 7-day rest period. In some embodiments, the dose is administered daily for 14 days, followed by an 8-day rest period. In some embodiments, the dose is administered daily for 14 days, followed by a 9-day rest period. In some embodiments, the dose is administered daily for 14 days, followed by a 10-day rest period. In some embodiments, the dose is administered daily for 14 days, followed by an 11-day rest period. In some embodiments, the dose is administered daily for 14 days, followed by a 12-day rest period. In some embodiments, the dose is administered daily for 14 days, followed by a 13-day rest period. In some embodiments, the dose is administered daily for 14 days, followed by a 14-day rest period.

[0502] In some embodiments, the dosage is administered daily for 30 days, followed by a 30 day rest period. In some embodiments, the dosage is administered daily for 30 days, followed by a 25-30 day rest period. In some embodiments, the dosage is administered daily for 30 days, followed by a 20-25 day rest period. In some embodiments, the dosage is administered daily for 30 days, followed by a 15-20 day rest period. In some embodiments, the dosage is administered daily for 30 days, followed by a 10-15 day rest period. In some embodiments, the dosage is administered daily for 30 days, followed by a 5-10 day rest period. In some embodiments, the dosage is administered daily for 30 days, followed by a 1-5 day rest period.

[0503] In some embodiments, the dosage is administered daily for 25-30 days, followed by a 30 day rest period. In some embodiments, the dosage is administered daily for 25-30 days, followed by a 25-30 day rest period. In some embodiments, the dosage is administered daily for 25-30 days, followed by a 20-25 day rest period. In some embodiments, the dosage is administered daily for 25-30 days, followed by a 15-20 day rest period. In some embodiments, the dosage is administered daily for 25-30 days, followed by a 10-15 day rest period. In some embodiments, the dosage is administered daily for 25-30 days, followed by a 5-10 day rest period. In some embodiments, the dosage is administered daily for 25-30 days, followed by a 1-5 day rest period.

[0504] In some embodiments, the dosage is administered daily for 20-25 days, followed by a 30 day rest period. In some embodiments, the dosage is administered daily for 20-25 days, followed by a 25-30 day rest period. In some embodiments, the dosage is administered daily for 20-25 days, followed by a 20-25 day rest period. In some embodiments, the dosage is administered daily for 20-25 days, followed by a 15-20 day rest period. In some embodiments, the dosage is administered daily for 20-25 days, followed by a 10-15 day rest period. In some embodiments, the dosage is administered daily for 20-25 days, followed by a 5-10 day rest period. In some embodiments, the dosage is administered daily for 20-25 days, followed by a 1-5 day rest period.

[0505] In some embodiments, the dose is administered daily for 15-20 days, followed by a 30 day rest period. In some embodiments, the dose is administered daily for 15-20 days, followed by a 25-30 day rest period. In some embodiments, the dose is administered daily for 15-20 days, followed by a 20-25 day rest period. In some embodiments, the dose is administered daily for 15-20 days, followed by a 15-20 day rest period. In some embodiments, the dose is administered daily for 15-20 days, followed by a 10-15 day rest period. In some embodiments, the dose is administered daily for 15-20 days, followed by a 5-10 day rest period. In some embodiments, the dose is administered daily for 15-20 days, followed by a 1-5 day rest period.

[0506] In any of the foregoing embodiments, the daily dose can be administered in a single dose or doses administered once per day, or in two or more divided doses administered multiple times per day. For example, the compounds described herein can be administered once per day, twice per day, three times per day, or four times per day.

[0507] In some embodiments, the subject's T3, T4, or TSH levels are monitored so that administration of the daily dose can be eliminated or reduced on any day that the T3, T4, or TSH levels fall below a predetermined threshold. If the T3, T4, or TSH levels rise above a predetermined threshold during a drug holiday, normal daily administration can be continued. EXAMPLES

[0508] Example 1 Alternative dosing study of Compound 2 in dogs The purpose of this study was to determine the effect of oral administration of Compound 2, once daily for 14 days followed by 14 days of every other day administration, on plasma cholesterol levels and indices of thyroid function in beagle dogs. Compound 2 was formulated with Lutrol F68 NF (Poloxomer 188) and carboxymethylcellulose (CMC; sodium salt / high viscosity) and administered as a suspension in 0.5% CMC / 1% Lutrol in deionized water. Twelve beagle dogs (9-15 kg) were randomized into six treatment groups (one male and one female per group) and administered Compound 2, at doses of 0.1, 0.3, 1, 3, or 10 mg / day, in a 0.5% CMC / 1% Lutrol F68 suspension, or vehicle, by gavage once daily for 14 days. At the end of the treatment cycle (cycle 1), the dogs were given a 4-week washout period and then entered a second 14-day treatment cycle. Cycle 2 used the same dosing paradigm as cycle 1, but animals were randomized into cycle 2 such that each combination dosing group from cycle 2 consisted of 4 different animals (2 males, 2 females). At the end of cycle 2, dosing was continued every other day for an additional 14 days (cycle 2 extension). Blood samples were then taken at baseline and appropriate time intervals and analyzed for total plasma cholesterol levels, total T4 (tT4), free T4 (fT4), total T3 (tT3), free T3 (fT3), and thyroid stimulating hormone (TSH).

[0509] Treatment with Compound 2 for 14 days resulted in a progressive dose-dependent reduction in total plasma cholesterol levels, with a mean reduction on day 15 of about 28 mg / dL or about 22% from baseline at a dose of 0.3 mg / kg / day and about 71 mg / dL or about 47% from baseline at the highest dose evaluated (10 mg / kg / day) (see Figure 1). The lowest dose of Compound 2 evaluated, 0.1 mg / kg / day, had the least effect on total plasma cholesterol levels (Figure 1). During the alternate day dosing period of Cycle 2 (Cycle 2 Extended), total plasma cholesterol levels in Compound 2-treated groups maintained a reduction similar to or greater than that observed after once-daily dosing compared to vehicle-treated animals (see Figure 2). Once-daily treatment with Compound 2 resulted in a dose-dependent decrease in serum tT4 (about 20-54%, see Figure 3), a dose-dependent decrease in fT4 (about 8-39%, see Figure 4), and a non-dose-dependent decrease in fT3 (about 15-32%, see Figure 6) from baseline levels. Compared to baseline levels, there was no meaningful change in tT3 levels in any of the Compound 2-treated groups beyond those observed in the vehicle-treated group (see Figure 5). The effect of once-daily Compound 2 treatment on serum TSH levels was variable, being completely suppressed in some animals and showing up to a four-fold increase in others on day 8. On day 15, TSH levels were non-dose-dependently decreased from baseline by about 6-27% in the Compound 2-treated groups (see Figure 7). During the cycle 2 extension period, the levels of tT4 and fT4 suppressed by once-daily treatment gradually recovered to levels approaching those of vehicle-treated animals (see Figures 8, 9). A more variable recovery of fT3 and TSH levels was observed, which was absent across all Compound 2 dose groups.

[0510] In conclusion, once-daily oral treatment of beagle dogs with compound 2 (0.1-10 mg / kg) for 14 days resulted in a dose-dependent decrease in mean total plasma cholesterol levels (up to 47% from baseline), accompanied by a dose-dependent decrease in serum tT4 levels, a dose-dependent decrease in fT4 levels, and a significant variation in serum TSH levels. Levels of tT3 were not affected by treatment, whereas levels of fT3 were decreased non-dose-dependently. Switching from once-daily to every-other-day administration of compound 2 in cycle 2 extension did not impair the cholesterol-lowering effect, but gradually restored levels of tT4 and fT4, and in some dose groups, fT3 and TSH, which were suppressed by once-daily oral compound 2 treatment. Thus, every-other-day administration is an effective alternative to once-daily administration with reduced effects on the thyroid hormone axis.

[0511] Example 2 First Alternative Dosing Study of Compound 1 in Dogs The purpose of this study is to investigate the effect of alternative dosing schedules on various clinical parameters in beagle dogs. Five beagle dogs per group of a single sex were randomized into five groups. One group received daily administration of vehicle only. Test groups received either: 1) daily administration of test sample; 2) one day of administration followed by a one-day washout period; 3) one day of administration followed by a two-day washout period; 4) three consecutive days of administration followed by a four-day washout period; or 5) five consecutive days of administration followed by a two-day washout period. Dogs are from a non-naive colony. Administration is by once-daily administration. Test sample is administered at a dose of 10 mg / kg of compound 1. Treatment is by oral gavage once daily on each treatment day and is 3 weeks (21 days) in duration. No recovery period is used. The vehicle for administration is 0.5% CMC / 1% Kolliphor P188 in deionized water, which is prepared once weekly and refrigerated. Food consumption is not monitored and veterinary tests are not performed unless necessary. Blood is drawn from each subject 7 days prior to the start of dosing, 4 days prior to the start of dosing, and 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 days after the start of dosing. Subjects are evaluated for their plasma cholesterol levels, aspartate transaminase (AST), and alanine transaminase (ALT) levels, and thyroid function. Total T4, total T3, free T4, free T3, and thyroid stimulating hormone are evaluated. After 22 days, data are compiled and subjected to appropriate statistical analysis.

[0512] Example 3 Second Alternative Dosing Study of Compound 1 in Dogs The purpose of this study is to investigate the effect of alternative dosing regimens on various clinical parameters in beagle dogs. Four, five, or six beagle dogs per group of a single sex were randomized into five groups. One group received daily administration of vehicle only. Test groups received either: 1) daily administration of test sample; 2) one day of dosing followed by a two-day washout period; 3) three consecutive days of dosing followed by a four-day washout period; or 4) four consecutive days of dosing followed by a three-day washout period. Dogs are from a non-naive colony. Treatment is by oral gavage once daily on each treatment day and is three weeks in duration. No recovery period is used. The vehicle for dosing is 0.5% CMC / 1% Lutrol F68 in deionized water, which is prepared once weekly and refrigerated. Food consumption is not monitored and veterinary examinations are not performed unless necessary. Blood is drawn from each subject every two days or every three to four days. Subjects are assessed for their plasma cholesterol levels, aspartate transaminase (AST) and alanine transaminase (ALT) levels, and thyroid function. Total T4, total T3, free T4, free T3, and thyroid stimulating hormone are assessed. After 14 days and again after 22 days, data are pooled and subjected to appropriate statistical analysis.

[0513] Example 4 Alternative dosing studies of Compound 1 in humans A Phase 2, randomized, double-blind, placebo-controlled, multicenter study will be conducted to evaluate the efficacy, safety, and tolerability of Compound 1 administered for 12 weeks, followed by a 4-week washout phase, in patients with primary hypercholesterolemia and nonalcoholic fatty liver disease. The objectives of the study are: 1) to evaluate the effect of Compound 1 compared to placebo on LDL-C after 12 weeks of treatment; 2) to evaluate the effect of Compound 1 compared to placebo on liver fat content, as measured by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF); 3) to evaluate the percent change from baseline in liver stiffness at week 12, as assessed by MR elastography (MRE); 4) to evaluate changes in other lipid parameters, including total cholesterol (TC), triglycerides (TG), non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, very-low-density lipoprotein cholesterol (VLDL-C), apolipoprotein B (apoB), and lipoprotein(a), [Lp(a)]; and 5) to evaluate safety and duration of effect from lipid assessments 4 weeks after treatment. Subjects were selected if they had at least 10% liver fat as assessed by MRI-proton density fat fraction (PDFF), were 18-75 years old at screening, had a body mass index (BMI) of 18.50-40.00 kg / m2, fasting serum LDL-C >130 mg / dL at screening or >110 on lipid-lowering medication, free T3 and free T4 within the normal range, and baseline values ​​of AST, ALT, ALP and total bilirubin established by at least two samples separated by at least several weeks (i.e., 4-12 weeks) where the difference between the levels of those repeated measurements was <20%.Subjects included in the study must also meet three of the following criteria: 1) type 2 diabetes on prescription medication or with HbA1c>5.7; 2) triglycerides>150mg / dL or taking prescription medication for high triglycerides; 3) systolic blood pressure>130 mmHg or diastolic blood pressure>85mmHg or taking prescription medication for hypertension; 4) waist circumference>40 inches (men) or>5 inches (women); or 5) HDL<40mg / dL (men) or <50md / dL (women) or taking prescription medication for low HDL. Subjects will be randomly assigned to one of four individual treatment arms: placebo orally (PO) daily; Compound 1 at a dose of 5mg PO daily; Compound 1 at a dose of 10mg PO daily; Compound 1 at a dose of 10mg PO every other day. Compound 1 will be provided in the form of tablets containing either 5mg or 10mg of Compound 1.

[0514] Subjects will be assessed for their total thyroid function at various times during the course of treatment, at the end of treatment, and 4 weeks after treatment. When assessing total thyroid function, total T4, total T3, free T4, free T3, and thyroid stimulating hormone will be evaluated. Subjects will also be monitored periodically for indicators of cardiac side effects, such as by monitoring blood pressure, C-reactive protein, cardiac troponin (cTnI), creatine kinase (CK), creatine kinase MB isoenzyme, by regular electrocardiograms and / or Holter monitors, or by other means as appropriate. Evaluations of thyroid function, cardiac health, and clinical endpoints will be performed periodically throughout the treatment period. Final measurements will be taken upon discontinuation of treatment at week 12 and after a 4-week washout period at week 16. After 16 weeks, data will be pooled and subjected to appropriate statistical analysis.

[0515] Example 5 Second Alternative Dosing Study of Compound 1 in Humans A Phase 2, randomized, double-blind, placebo-controlled, multicenter study will be conducted to evaluate the efficacy, safety, and tolerability of Compound 1 administered for 12 weeks, followed by a 4-week washout phase, in patients with primary hypercholesterolemia and nonalcoholic fatty liver disease. The objectives of the study are: 1) to evaluate the effect of Compound 1 compared to placebo on LDL-C after 12 weeks of treatment; 2) to evaluate the effect of Compound 1 compared to placebo on liver fat content, as measured by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF); 3) to evaluate the percent change from baseline in liver stiffness at week 12, as assessed by MR elastography (MRE); 4) to evaluate changes in other lipid parameters, including total cholesterol (TC), triglycerides (TG), non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, very-low-density lipoprotein cholesterol (VLDL-C), apolipoprotein B (apoB), and lipoprotein(a), [Lp(a)]; and 5) to evaluate safety and duration of effect from lipid assessments 4 weeks after treatment. Subjects were selected if they had at least 10% liver fat as assessed by MRI-proton density fat fraction (PDFF), were 18-75 years old at screening, had a body mass index (BMI) of 18.50-40.00 kg / m2, fasting serum LDL-C >130 mg / dL at screening or >110 on lipid-lowering medication, free T3 and free T4 within the normal range, and baseline values ​​of AST, ALT, ALP and total bilirubin established by at least two samples separated by at least several weeks (i.e., 4-12 weeks) where the difference between the levels of those repeated measurements was <20%.Subjects included in the study must also meet three of the following criteria: 1) type 2 diabetes on prescription medication or with HbA1c>5.7; 2) triglycerides>150mg / dL or taking prescription medication for high triglycerides; 3) systolic blood pressure>130mmHg or diastolic blood pressure>85mmHg or taking prescription medication for hypertension; 4) waist circumference>40 inches (men) or>5 inches (women); or 5) HDL<40mg / dL (men) or <50mg / dL (women) or taking prescription medication for low HDL. Subjects are randomly assigned to one of seven individual treatment arms: daily placebo orally (PO); a daily dose of 5 mg Compound 1 PO after a loading dose of 250 mg Compound 1; a daily dose of 10 mg Compound 1 PO after a loading dose of 250 mg Compound 1; a daily dose of 10 mg Compound 1 PO after a loading dose of 250 mg Compound 1; a daily dose of 5 mg Compound 1 PO after a loading dose of 100 mg Compound 1; a daily dose of 10 mg Compound 1 PO after a loading dose of 100 mg Compound 1; and a dose of 10 mg Compound 1 PO after a loading dose of 100 mg Compound 1. Compound 1 is provided in the form of a tablet containing either 5 mg or 10 mg Compound 1.

[0516] Subjects will be assessed for their total thyroid function at various times during the course of treatment, at the end of treatment, and 4 weeks after treatment. When assessing total thyroid function, total T4, total T3, free T4, free T3, and thyroid stimulating hormone will be evaluated. Subjects will also be monitored periodically for indicators of cardiac side effects, such as by monitoring blood pressure, C-reactive protein, cardiac troponin (cTnI), creatine kinase (CK), creatine kinase MB isoenzyme, by regular electrocardiograms and / or Holter monitors, or by other means as appropriate. Evaluations of thyroid function, cardiac health, and clinical endpoints will be performed periodically throughout the treatment period. Final measurements will be taken upon discontinuation of treatment at week 12 and after a 4-week washout period at week 16. After 16 weeks, data will be pooled and subjected to appropriate statistical analysis.

[0517] Example 6 Alternative dosing studies of Compound 1 in humans A Phase 1b, randomized, double-blind, placebo-controlled study will be conducted to evaluate the efficacy, safety, and tolerability of Compound 1 administered for 12 weeks, followed by a 4-week washout phase, in patients with primary hypercholesterolemia and nonalcoholic fatty liver disease.

[0518] In this current clinical trial, the maximum cumulative weekly dose will not exceed 40 mg. Doses of Compound 1 of 5 mg daily and up to 40 mg once weekly over a 4-week treatment period in this Phase 1b study result in dose- and / or schedule-dependent reductions in LDL-C and triglycerides. The predicted systemic exposure (AUC0-168h [i.e., 1-week exposure]) of the active metabolite at 40 mg once weekly is 5570 ng·hr / mL. Pharmacokinetic modeling indicates an AUC0-168h of 18300 ng·hr / mL. Thus, the estimated exposure in humans receiving 40 mg once weekly is estimated to be approximately 3-fold lower than the previously determined no observable adverse effect level (NOAEL) exposure of 5 mg / kg / day.

[0519] Approximately 32 subjects will be enrolled and randomly assigned in a 6:2 ratio (Compound 1:placebo) to one of the following treatment groups: (1) 5 mg Compound 1 or placebo daily; (2) 20 mg Compound 1 or placebo once a week; (3) 40 mg Compound 1 or placebo once a week; (4) 10 mg Compound 1 or placebo every other day. The primary endpoint is the percent change in LDL-C from the baseline visit to day 29. Either a 20% reduction in LDL-C or a reduction in LDL-C into the normal range will be considered clinically meaningful. Subjects will also be monitored for adverse effects and / or clinically relevant changes in health status or results of laboratory analyses. Each subject will be screened for changes in health status or laboratory results 28 days after the last administration of test sample.

[0520] Clinical parameters observed during the study may include one or more of the following: physical examination; monitoring of concomitant medications; assessment / monitoring of hyperthyroidism / thyrotoxicosis; vitals (seated for ≥5 min); weight; assessment of alcohol intake; assessment / monitoring of lifestyle habits; 12-lead ECG (supine for ≥10 min); assessment / monitoring of drug compliance; AE / SAE assessment; and / or 24-hour Holter monitoring. A complete physical examination may include, but is not limited to: general appearance, skin, HEENT (including neck / throat exam to assess thyroid), respiratory exam, assessment of the cardiovascular system including the presence or absence of heart rhythm and cardiac abnormalities (e.g., gallop, murmur, enlarged heart), abdominal exam, musculoskeletal system, neurological exam (including reflex testing) to document the presence of abnormalities in mental function, status, motor function, and sensory function, gastrointestinal tract, genitourinary system if appropriate, and / or any additional assessments necessary to establish or evaluate baseline status. Additionally, laboratory tests may be performed, including any one or more of the following:Hematology including platelet count, WBC with differential (% and absolute counts), hematocrit, hemoglobin, RBC, mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), and mean cellular hemoglobin (MCH); lipid profile (blinded after randomization) including LDL-C, non-HDL-C, VLDL-C (calculated), total cholesterol, triglycerides, HDL-C, Lp(a), and apoB via direct beta quantification; serum chemistry including BUN, creatinine, calcium, glucose, sodium, potassium, chloride, bicarbonate, phosphorus, uric acid, and creatinine kinase; liver function including AST (SGOT), ALT (SGPT), alkaline phosphatase (ALP), and bilirubin (total, direct, and indirect). panel; further liver tests including INR / PT, total protein, albumin, sex hormone binding globulin (SHBG), and thyroxine binding globulin (TBG); thyroid panel (blinded after randomization) including TSH, total and free T4, and total and free T3; cardiac biomarkers including CK, CK-MB, and cardiac troponin I (cTnI); urinalysis including color, appearance specific gravity pH, protein, leukocyte esterase, glucose, blood ketones, bilirubin urobilinogen, nitrates, and microscopic analysis if abnormal; other samples including FSH (postmenopausal women), serum pregnancy, HbsAg, HCV, and HIV serology, HbA1C, fasting insulin and glucose for HOMA, alcohol and drug testing, and PK samples. Additional clinical parameters may be monitored or evaluated as needed.

Claims

1. 1. A composition for use in a method for treating non-alcoholic fatty liver disease, comprising: The method comprises administering to a subject in need thereof a dose of a compound every other day; The compound 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof; The composition, wherein the dose is from about 2.5 mg to about 10 mg.

2. The method comprises, in order: a loading phase consisting of administering a loading dose of the compound to a subject in need thereof; Optionally, a drug holiday, and Administering a maintenance dose of the compound to a subject The composition of claim 1 comprising:

3. 3. The composition of claim 2, wherein the loading dose is from about 0.5 mg to about 10 mg.

4. 4. The composition of claim 2 or 3, wherein the loading dose is 5 mg.

5. 4. The composition of claim 2 or 3, wherein the loading dose is 10 mg.

6. 6. The composition according to claim 2, wherein the loading phase is from 1 to 30 days.

7. The composition of claim 6, wherein the loading phase is 14 days.

8. The composition of any one of claims 2 to 7, wherein the maintenance dose is between 0.5 mg and 10 mg.

9. 9. The composition of claim 8, wherein the maintenance dose is 5 mg.

10. 9. The composition of claim 8, wherein the maintenance dose is 2.5 mg.

11. 11. The composition of any one of claims 2 to 10, wherein the drug holiday period is from 1 to 30 days.

12. 2. The composition of claim 1, wherein the dose is about 10 mg.

13. 2. The composition of claim 1, wherein the dose is about 5 mg.

14. 2. The composition of claim 1, wherein the dose is about 2.5 mg.

Images